| 1 | Celebrating the 90th birthday of the scientist who discovered statins: Akira Endō | 2.2 | 1 | Citations (PDF) |
| 2 | Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors: analysis of LIPIDOGRAM2015 and LIPIDOGEN2015 studies | 1.2 | 3 | Citations (PDF) |
| 3 | The role of nutraceuticals in heart failure muscle wasting as a result of inflammatory activity. The International Lipid Expert Panel (ILEP) Position Paper. | 1.2 | 3 | Citations (PDF) |
| 4 | Perivascular Adipose Tissue: Pathophysiological Links With Inflammation, Atherosclerosis, and Thrombosis | 2.0 | 20 | Citations (PDF) |
| 5 | Contrast-induced Nephropathy in Non-cardiac Vascular Procedures, A Narrative Review: Part 2 | 1.4 | 5 | Citations (PDF) |
| 6 | Contrast-induced Nephropathy in Non-cardiac Vascular Procedures, A Narrative Review: Part 1 | 1.4 | 6 | Citations (PDF) |
| 7 | Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview | 2.1 | 11 | Citations (PDF) |
| 8 | Thromboprophylaxis in Patients with COVID-19: Systematic Review of National and International Clinical Guidance Reports | 1.4 | 24 | Citations (PDF) |
| 9 | Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies | 1.2 | 12 | Citations (PDF) |
| 10 | Incidence of contrast-induced acute kidney injury in patients with acute mesenteric ischemia and identification of potential predictive factors | 1.2 | 1 | Citations (PDF) |
| 11 | Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications | 2.1 | 11 | Citations (PDF) |
| 12 | Optimal Management of Asymptomatic Carotid Stenosis in 2021: The Jury is Still Out. An International, Multispecialty, Expert Review and Position Statement | 1.7 | 14 | Citations (PDF) |
| 13 | Carotid Artery Pathology in Inflammatory Diseases | 0.4 | 5 | Citations (PDF) |
| 14 | Prevalence of statin intolerance: a meta-analysis | 2.2 | 244 | Citations (PDF) |
| 15 | The burden of carotid-related strokes | 1.8 | 3 | Citations (PDF) |
| 16 | The Association between Coffee and Caffeine Consumption and Renal Function: Insight from Individual-Level Data, Mendelian Randomization, and Meta-Analysis | 1.2 | 2 | Citations (PDF) |
| 17 | Relationship between Low-Density Lipoprotein Cholesterol, Lipid Lowering Agents and the Risk of Stroke: A meta-analysis of Observational studies (n=355,591) and Randomized Controlled Trials (n=165,988). | 1.2 | 5 | Citations (PDF) |
| 18 | Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress | 2.5 | 1 | Citations (PDF) |
| 19 | C‐reactive protein–albumin ratio and erectile dysfunction | 1.9 | 0 | Citations (PDF) |
| 20 | Optimal Management of Asymptomatic Carotid Stenosis: Counterbalancing the Benefits with the Potential Risks | 5.1 | 1 | Citations (PDF) |
| 21 | Vascular Dysfunction of COVID-19 Is Partially Reverted in the Long-Term | 12.8 | 47 | Citations (PDF) |
| 22 | Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from <i>the International Lipid Expert Panel</i> (ILEP) | 9.1 | 51 | Citations (PDF) |
| 23 | Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis | 1.8 | 0 | Citations (PDF) |
| 24 | Optimal management of asymptomatic carotid stenosis in 2021: the jury is still out. An international, multispecialty, expert review and position statement | 1.4 | 2 | Citations (PDF) |
| 25 | Comparison of Recent Practice Guidelines for the Management of Patients With Asymptomatic Carotid Stenosis | 2.0 | 6 | Citations (PDF) |
| 26 | Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors | 7.0 | 78 | Citations (PDF) |
| 27 | Low serum albumin: A neglected predictor in patients with cardiovascular disease | 2.6 | 99 | Citations (PDF) |
| 28 | Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation | 5.0 | 4 | Citations (PDF) |
| 29 | Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease | 5.9 | 20 | Citations (PDF) |
| 30 | Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: An Overview | 1.5 | 16 | Citations (PDF) |
| 31 | Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis | 6.1 | 52 | Citations (PDF) |
| 32 | The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP) | 5.6 | 90 | Citations (PDF) |
| 33 | Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study | 2.8 | 4 | Citations (PDF) |
| 34 | Diabetes Mellitus and Noncardiac Atherosclerotic Vascular Disease—Pathogenesis and Pharmacological Treatment Options | 2.8 | 14 | Citations (PDF) |
| 35 | More Good News on Statins and COVID-19 | 1.9 | 10 | Citations (PDF) |
| 36 | The association between serum uric acid levels and 10-year cardiovascular disease incidence: results from the ATTICA prospective study | 1.1 | 15 | Citations (PDF) |
| 37 | Homocysteine and diabetes: Role in macrovascular and microvascular complications | 2.6 | 52 | Citations (PDF) |
| 38 | Endocan: a new marker of endothelial function | 1.8 | 18 | Citations (PDF) |
| 39 | Can We Decrease Epicardial and Pericardial Fat in Patients With Diabetes? | 2.8 | 24 | Citations (PDF) |
| 40 | Editorial: The year in hyperlipidaemia | 1.8 | 2 | Citations (PDF) |
| 41 | Management of Patients with Asymptomatic Carotid Stenosis May Need to Be Individualized: A Multidisciplinary Call for Action | 5.1 | 22 | Citations (PDF) |
| 42 | Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk | 5.0 | 151 | Citations (PDF) |
| 43 | Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease | 2.3 | 59 | Citations (PDF) |
| 44 | The effect of statins on semen parameters in patients with hypercholesterolemia: A systematic review | 3.3 | 3 | Citations (PDF) |
| 45 | Cilostazol for intermittent claudication | 2.4 | 23 | Citations (PDF) |
| 46 | Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP) | 5.9 | 47 | Citations (PDF) |
| 47 | Narrative Review of Carotid disease and the kidney | 1.8 | 6 | Citations (PDF) |
| 48 | Management of patients with asymptomatic carotid stenosis may need to be individualized: a multidisciplinary call for action. Republication of J Stroke 2021;23:202-212 | 1.4 | 5 | Citations (PDF) |
| 49 | Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease) | 1.4 | 5 | Citations (PDF) |
| 50 | Have We Learnt all from IMPROVE-IT? Part II. Subanalyses of the Effects of Ezetimibe Added to Statin Therapy on Selected Clinical and Laboratory Outcomes, Cost-Effectiveness, Guidelines, and Clinical Implications | 1.4 | 4 | Citations (PDF) |
| 51 | Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study | 2.6 | 3 | Citations (PDF) |
| 52 | Narrative review on clinical considerations for patients with diabetes and COVID‐19: More questions than answers | 2.1 | 12 | Citations (PDF) |
| 53 | Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players | 2.3 | 15 | Citations (PDF) |
| 54 | Comment on “Long-term Prognosis After Elective Abdominal Aortic Aneurysm Repair is Poor in Women and Men: The Challenges Remain” | 4.9 | 0 | Citations (PDF) |
| 55 | Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study | 2.6 | 8 | Citations (PDF) |
| 56 | The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study | 2.6 | 11 | Citations (PDF) |
| 57 | Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study | 2.5 | 19 | Citations (PDF) |
| 58 | Statin use and renal function after aortic aneurysm repair procedures | 1.6 | 1 | Citations (PDF) |
| 59 | Statins and diabetes mellitus progression: a fly in the ointment? | 10.6 | 7 | Citations (PDF) |
| 60 | The Role of n-3 Fatty Acids in Cardiovascular Disease: Back to the Future | 2.0 | 21 | Citations (PDF) |
| 61 | Associations of serum uric acid with total and cause-specific mortality: Findings from individuals and pooling prospective studies | 1.2 | 29 | Citations (PDF) |
| 62 | Impact of serum 25-hydroxyvitamin D 25(OH) on telomere attrition: A Mendelian Randomization study | 5.6 | 8 | Citations (PDF) |
| 63 | Rationale for screening selected patients for asymptomatic carotid artery stenosis | 2.2 | 15 | Citations (PDF) |
| 64 | Low-carbohydrate diet: forget restriction, replace with balance! | 2.2 | 5 | Citations (PDF) |
| 65 | Effect of Dietary Insulinemia on All-Cause and Cause-Specific Mortality: Results From a Cohort Study | 3.2 | 8 | Citations (PDF) |
| 66 | Cholesterol, carotid artery disease and stroke: what the vascular specialist needs to know | 1.8 | 15 | Citations (PDF) |
| 67 | Metabolic Syndrome and Abnormal Peri-Organ or Intra-Organ Fat (APIFat) Deposition in Chronic Obstructive Pulmonary Disease: An Overview | 3.5 | 11 | Citations (PDF) |
| 68 | Diabetes and carotid artery disease: a narrative review | 1.8 | 15 | Citations (PDF) |
| 69 | Adverse Impact of Desulfovibrio spp. and Beneficial Role of Anaerostipes spp. on Renal Function: Insights from a Mendelian Randomization Analysis | 4.6 | 21 | Citations (PDF) |
| 70 | Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile | 2.3 | 22 | Citations (PDF) |
| 71 | Half a century and more of PhD theses by published papers | 2.9 | 2 | Citations (PDF) |
| 72 | CETP inhibition in the REVEAL trial: could we aim higher? | 1.2 | 1 | Citations (PDF) |
| 73 | NAFLD and Statins | 2.2 | 3 | Citations (PDF) |
| 74 | Weight-centric pharmacological management of type 2 diabetes mellitus – An essential component of cardiovascular disease prevention | 2.6 | 12 | Citations (PDF) |
| 75 | Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic | 1.2 | 72 | Citations (PDF) |
| 76 | Vascular surgical procedures in patients with familial hypercholesterolaemia: is it too late? | 2.2 | 0 | Citations (PDF) |
| 77 | Potato consumption is associated with total and cause-specific mortality: a population-based cohort study and pooling of prospective studies with 98,569 participants | 1.2 | 8 | Citations (PDF) |
| 78 | Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP) | 5.6 | 35 | Citations (PDF) |
| 79 | Fetal/Infant Origins of Adult Vascular Disease | 1.4 | 3 | Citations (PDF) |
| 80 | Commentary: From mice to men: In search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be based | 5.0 | 12 | Citations (PDF) |
| 81 | Apolipoprotein B/Apolipoprotein A-I Ratio Is a Better Predictor of Cancer Mortality Compared with C-Reactive Protein: Results from Two Multi-Ethnic US Populations | 2.6 | 8 | Citations (PDF) |
| 82 | Non-coronary atherosclerotic cardiovascular disease in patients with familial hypercholesterolaemia | 2.2 | 14 | Citations (PDF) |
| 83 | Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP) | 9.0 | 18 | Citations (PDF) |
| 84 | Excessive “orthotopic” fat accumulation: Links with cardiometabolic diseases and potential drug treatment | 4.2 | 7 | Citations (PDF) |
| 85 | Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials | 2.6 | 32 | Citations (PDF) |
| 86 | Association of types of dietary fats and all-cause and cause-specific mortality: A prospective cohort study and meta-analysis of prospective studies with 1,164,029 participants | 5.6 | 54 | Citations (PDF) |
| 87 | Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement | 2.0 | 21 | Citations (PDF) |
| 88 | The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study | 2.1 | 20 | Citations (PDF) |
| 89 | Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications | 2.5 | 28 | Citations (PDF) |
| 90 | Abnormal Peri-organ-Intra-organ Fat (APIFat) and Rheumatoid Arthritis: An Under-investigated Link for Increased Cardiovascular Risk? | 1.4 | 6 | Citations (PDF) |
| 91 | Adverse impact of egg consumption on fatty liver is partially explained by cardiometabolic risk factors: A population-based study | 5.6 | 8 | Citations (PDF) |
| 92 | Endocrine Disease as a Cause of Cardiovascular Disease: Current Perspectives | 2.3 | 0 | Citations (PDF) |
| 93 | Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes | 2.3 | 15 | Citations (PDF) |
| 94 | Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study | 5.6 | 37 | Citations (PDF) |
| 95 | The Association Between Abdominal Aortic Aneurysms With Cardiovascular and Noncardiovascular Diseases | 2.0 | 5 | Citations (PDF) |
| 96 | Statin use in patients with diabetes: one drug, multiple benefits | 1.8 | 2 | Citations (PDF) |
| 97 | Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease | 2.3 | 23 | Citations (PDF) |
| 98 | Adiposity May Moderate the Link Between Choline Intake and Non-alcoholic Fatty Liver Disease | 3.2 | 17 | Citations (PDF) |
| 99 | Dietary choline is positively related to overall and cause-specific mortality: results from individuals of the National Health and Nutrition Examination Survey and pooling prospective data | 2.7 | 22 | Citations (PDF) |
| 100 | Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis | 3.8 | 38 | Citations (PDF) |
| 101 | Increased risk for cardiovascular disease in patients with obstructive sleep apnoea syndrome‐chronic obstructive pulmonary disease (overlap syndrome) | 2.1 | 16 | Citations (PDF) |
| 102 | Iron absorption, bone marrow fat and hematopoiesis in heart failure: Additional mechanisms of action for sodium-glucose co-transporter 2 inhibitors (SGLT2i)? | 2.6 | 4 | Citations (PDF) |
| 103 | Association of Empirical Dietary Atherogenic Indices with All-Cause and Cause-Specific Mortality in a Multi-Ethnic Adult Population of the United States | 4.6 | 15 | Citations (PDF) |
| 104 | Reduced Serum Vitamin D Levels Are Associated with Insulin Resistance in Patients with Obstructive Sleep Apnea Syndrome | 2.2 | 10 | Citations (PDF) |
| 105 | Egg Consumption and Risk of Total and Cause-Specific Mortality: An Individual-Based Cohort Study and Pooling Prospective Studies on Behalf of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group | 3.2 | 29 | Citations (PDF) |
| 106 | Perirenal Adiposity and Other Excessive Intra- and Peri-Organ Fat Depots: What Is the Connection? | 2.0 | 18 | Citations (PDF) |
| 107 | Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement | 1.4 | 23 | Citations (PDF) |
| 108 | Lower carbohydrate diets and all-cause and cause-specific mortality: a population-based cohort study and pooling of prospective studies | 2.2 | 118 | Citations (PDF) |
| 109 | Arterial Stiffness in the Heart Disease of CKD | 0.4 | 140 | Citations (PDF) |
| 110 | Management of patients with type 2 diabetes mellitus and acute coronary syndrome: Better be safe than sorry! | 2.6 | 5 | Citations (PDF) |
| 111 | Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials | 9.0 | 101 | Citations (PDF) |
| 112 | Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence | 5.0 | 41 | Citations (PDF) |
| 113 | Predictive models with the use of omics and supervised machine learning to diagnose non-alcoholic fatty liver disease: A “non-invasive alternative” to liver biopsy? | 5.0 | 18 | Citations (PDF) |
| 114 | Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient! | 1.2 | 35 | Citations (PDF) |
| 115 | Mean platelet volume and coronary artery disease | 1.8 | 43 | Citations (PDF) |
| 116 | Endocan and Erectile Dysfunction | 2.0 | 6 | Citations (PDF) |
| 117 | Association of ideal cardiovascular health metrics with serum uric acid, inflammation and atherogenic index of plasma: A population-based survey | 1.2 | 29 | Citations (PDF) |
| 118 | Consumption of dairy product and its association with total and cause specific mortality – A population-based cohort study and meta-analysis | 5.6 | 48 | Citations (PDF) |
| 119 | Are we ready for a gender-specific approach in interventional cardiology? | 2.2 | 38 | Citations (PDF) |
| 120 | Associations between risk of overall mortality, cause-specific mortality and level of inflammatory factors with extremely low and high high-density lipoprotein cholesterol levels among American adults | 2.2 | 37 | Citations (PDF) |
| 121 | Ideal cardiovascular health associated with fatty liver: Results from a multi-ethnic survey | 1.2 | 11 | Citations (PDF) |
| 122 | A higher ratio of refined grain to whole grain is associated with a greater likelihood of chronic kidney disease: a population-based study | 2.7 | 16 | Citations (PDF) |
| 123 | Prehypertension, the Risk of Hypertension and Events | 0.0 | 0 | Citations (PDF) |
| 124 | Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus | 2.3 | 49 | Citations (PDF) |
| 125 | Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review | 1.4 | 18 | Citations (PDF) |
| 126 | Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text | 1.4 | 40 | Citations (PDF) |
| 127 | Dietary inflammatory index and cardiometabolic risk in US adults | 1.2 | 89 | Citations (PDF) |
| 128 | Statin Intolerance | 1.6 | 40 | Citations (PDF) |
| 129 | Carotid Bifurcation Geometry as Assessed by Ultrasound is Associated with Early Carotid Atherosclerosis | 1.2 | 7 | Citations (PDF) |
| 130 | Prosarcopenic Effects of Statins May Limit Their Effectiveness in Patients with Heart Failure | 14.8 | 22 | Citations (PDF) |
| 131 | The potential role of statins in preeclampsia and dyslipidemia during gestation: a narrative review | 4.1 | 35 | Citations (PDF) |
| 132 | Higher dietary acid load is associated with higher likelihood of peripheral arterial disease among American adults | 2.6 | 24 | Citations (PDF) |
| 133 | Statin loading in cardiovascular surgery | 1.8 | 28 | Citations (PDF) |
| 134 | Cardiovascular Risk Factors and Peripheral Arterial Disease 2018, , 189-200 | | 0 | Citations (PDF) |
| 135 | Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | 12.1 | 85 | Citations (PDF) |
| 136 | Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials | 2.0 | 20 | Citations (PDF) |
| 137 | Carotid Artery Stenting Has a Role in the Management of Asymptomatic Carotid Stenosis, but This Is Currently Small | 2.0 | 0 | Citations (PDF) |
| 138 | Lipid-lowering treatment in peripheral artery disease | 4.1 | 22 | Citations (PDF) |
| 139 | The link between insulin resistance parameters and serum uric acid is mediated by adiposity | 1.2 | 61 | Citations (PDF) |
| 140 | Dyslipidaemia in the elderly: to treat or not to treat? | 2.9 | 8 | Citations (PDF) |
| 141 | Effects of selected dietary constituents on high-sensitivity C-reactive protein levels in U.S. adults | 3.9 | 65 | Citations (PDF) |
| 142 | Appropriate Patient Selection for Carotid Revascularization Procedures is Urgently Needed | 2.0 | 7 | Citations (PDF) |
| 143 | Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis | 11.2 | 59 | Citations (PDF) |
| 144 | Lipid accumulation product and triglycerides/glucose index are useful predictors of insulin resistance | 2.6 | 114 | Citations (PDF) |
| 145 | Non-alcoholic fatty liver disease and cardiovascular risk: an update | 2.4 | 10 | Citations (PDF) |
| 146 | Inverse association between serum antioxidant levels and inflammatory markers is moderated by adiposity: a report based on a large representative population sample of American adults | 2.7 | 13 | Citations (PDF) |
| 147 | Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin‐associated muscle symptoms, under blinded and open‐label conditions | 9.1 | 92 | Citations (PDF) |
| 148 | Lipids: a personal view of the past decade | 2.0 | 5 | Citations (PDF) |
| 149 | Adiposity mediates the association between whole grain consumption, glucose homeostasis and insulin resistance: findings from the US NHANES | 3.8 | 9 | Citations (PDF) |
| 150 | Non-alcoholic fatty liver disease and colorectal cancer: A marker of risk or common causation? | 5.0 | 16 | Citations (PDF) |
| 151 | Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic survey | 2.2 | 28 | Citations (PDF) |
| 152 | Abnormal Peri-Organ or Intra-Organ Fat Deposition and Vascular Risk | 2.0 | 26 | Citations (PDF) |
| 153 | The Role of Nutraceuticals in Statin Intolerant Patients | 2.6 | 213 | Citations (PDF) |
| 154 | Depression in cardiac and non-cardiac vascular diseases: Current evidence and future perspectives | 2.2 | 1 | Citations (PDF) |
| 155 | Link between plasma trans-fatty acid and fatty liver is moderated by adiposity | 2.2 | 18 | Citations (PDF) |
| 156 | Mean Platelet Volume and Platelet Distribution Width in Patients With Obstructive Sleep Apnea Syndrome and Concurrent Chronic Obstructive Pulmonary Disease | 1.8 | 20 | Citations (PDF) |
| 157 | Contrast-induced acute kidney injury in diabetes mellitus: Clinical relevance and predisposing factors. Could statins be of benefit? | 2.6 | 15 | Citations (PDF) |
| 158 | Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials | 3.9 | 37 | Citations (PDF) |
| 159 | Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies – part 1 | 2.8 | 14 | Citations (PDF) |
| 160 | Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies – Part 2 | 2.8 | 8 | Citations (PDF) |
| 161 | Leptin, cardiovascular diseases and type 2 diabetes mellitus | 7.1 | 210 | Citations (PDF) |
| 162 | Statins and substantially increased <scp>ALT</scp> values at baseline | 3.0 | 0 | Citations (PDF) |
| 163 | Left atrial volume: An independent predictor of cardiovascular outcomes | 2.2 | 9 | Citations (PDF) |
| 164 | Effect of Metformin on Plasma Fibrinogen Concentrations: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials | 2.3 | 3 | Citations (PDF) |
| 165 | Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome? | 1.4 | 92 | Citations (PDF) |
| 166 | Lipoprotein(a) Levels in Patients With Abdominal Aortic Aneurysm | 2.0 | 36 | Citations (PDF) |
| 167 | Marital Status, Cardiovascular Diseases, and Cardiovascular Risk Factors: A Review of the Evidence | 2.2 | 103 | Citations (PDF) |
| 168 | The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement | 5.0 | 218 | Citations (PDF) |
| 169 | Semaglutide, lipid-lowering drugs, and NAFLD | 22.3 | 12 | Citations (PDF) |
| 170 | Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684–1692 | 9.5 | 2 | Citations (PDF) |
| 171 | Dyslipidaemia in type 2 diabetes mellitus | 1.8 | 30 | Citations (PDF) |
| 172 | Adiponectin, lipids and atherosclerosis | 4.1 | 131 | Citations (PDF) |
| 173 | Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial | 5.0 | 19 | Citations (PDF) |
| 174 | Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis | 2.0 | 45 | Citations (PDF) |
| 175 | Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: A systematic review and meta-analysis of controlled trials | 2.6 | 19 | Citations (PDF) |
| 176 | Letter to the editor: Treating nonalcoholic fatty liver disease with statins. Are all statins equal? | 3.5 | 2 | Citations (PDF) |
| 177 | The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials | 9.0 | 20 | Citations (PDF) |
| 178 | Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation | 6.1 | 304 | Citations (PDF) |
| 179 | Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials | 6.1 | 39 | Citations (PDF) |
| 180 | The impact of metabolic syndrome and its components on perioperative outcomes after elective laparotomy - A prospective observational study | 2.1 | 6 | Citations (PDF) |
| 181 | Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs | 2.6 | 33 | Citations (PDF) |
| 182 | Response letter: Statins and non-alcoholic steatohepatitis | 5.0 | 1 | Citations (PDF) |
| 183 | Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel | 6.1 | 242 | Citations (PDF) |
| 184 | Time for new low density lipoprotein cholesterol (LDL-C) targets? | 2.3 | 2 | Citations (PDF) |
| 185 | Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis | 2.2 | 44 | Citations (PDF) |
| 186 | Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta-analysis of controlled trials | 9.0 | 4 | Citations (PDF) |
| 187 | Cardiovascular disease prevention strategies for type 2 diabetes mellitus | 2.3 | 36 | Citations (PDF) |
| 188 | Carotid Bifurcation Geometry and Atherosclerosis | 2.0 | 44 | Citations (PDF) |
| 189 | Statins and non-alcoholic steatohepatitis | 5.0 | 5 | Citations (PDF) |
| 190 | Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial | 2.6 | 5 | Citations (PDF) |
| 191 | The Relation Between No-Reflow Phenomenon and Complete Blood Count Parameters | 2.0 | 29 | Citations (PDF) |
| 192 | Contrast-Induced Acute Kidney Injury in Patients Undergoing Carotid Artery Stenting: An Underestimated Issue | 2.0 | 24 | Citations (PDF) |
| 193 | Editorial: Natural Products as the Integral Part of the Therapy? | 2.3 | 4 | Citations (PDF) |
| 194 | Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel | 1.2 | 208 | Citations (PDF) |
| 195 | Lung and kidney: a dangerous liaison? A population-based cohort study in COPD patients in Italy | 2.6 | 24 | Citations (PDF) |
| 196 | Homocysteine and Non-Cardiac Vascular Disease | 2.3 | 26 | Citations (PDF) |
| 197 | Dietary food patterns and glucose/insulin homeostasis: a cross-sectional study involving 24,182 adult Americans | 3.8 | 43 | Citations (PDF) |
| 198 | Dietary patterns, plasma vitamins and Trans fatty acids are associated with peripheral artery disease | 3.8 | 30 | Citations (PDF) |
| 199 | Vitamin D status and circulating biomarkers of endothelial dysfunction and inflammation in non-diabetic obese individuals: a pilot study | 1.2 | 27 | Citations (PDF) |
| 200 | Editorial: Lipoprotein (a), More than Just Cholesterol? | 2.5 | 6 | Citations (PDF) |
| 201 | More on carotid atherosclerosis and ezetimibe | 1.4 | 7 | Citations (PDF) |
| 202 | Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials | 12.1 | 35 | Citations (PDF) |
| 203 | Lipoprotein (a) and Cardiovascular Risk: The Show Must go on | 2.5 | 20 | Citations (PDF) |
| 204 | Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management | 2.3 | 40 | Citations (PDF) |
| 205 | The Heart Outcomes Prevention Evaluation (HOPE)-3 trial: where do we stand? | 4.1 | 1 | Citations (PDF) |
| 206 | Editorial: Your VISION Will Become Clear Only When You Look Into Your Heart | 1.4 | 0 | Citations (PDF) |
| 207 | Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed? | 1.4 | 9 | Citations (PDF) |
| 208 | The impact of statin therapy on plasma levels of von Willebrand factor antigen | 4.4 | 150 | Citations (PDF) |
| 209 | Statins induce regression of carotid artery stenosis: Fact or fiction? | 2.2 | 3 | Citations (PDF) |
| 210 | Critical Issues and Controversies in Carotid Artery Stenosis | 2.0 | 1 | Citations (PDF) |
| 211 | Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials | 3.7 | 54 | Citations (PDF) |
| 212 | Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials | 9.0 | 62 | Citations (PDF) |
| 213 | Statins, renal function and homocysteine | 3.6 | 0 | Citations (PDF) |
| 214 | Lipid-modifying effects of nutraceuticals: An evidence-based approach | 2.8 | 159 | Citations (PDF) |
| 215 | Non-alcoholic fatty liver disease and dyslipidemia: An update | 5.0 | 407 | Citations (PDF) |
| 216 | Assessment of postprandial triglycerides in clinical practice: Validation in a general population and coronary heart disease patients | 2.0 | 22 | Citations (PDF) |
| 217 | Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms | 1.2 | 154 | Citations (PDF) |
| 218 | Effects of Quercetin on Blood Pressure: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials | 4.3 | 230 | Citations (PDF) |
| 219 | Can the effects of gender, menopause and ageing on lipid levels be differentiated? | 2.5 | 3 | Citations (PDF) |
| 220 | Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis | 3.7 | 26 | Citations (PDF) |
| 221 | Cardiovascular effects of sodium–glucose cotransporter 2 inhibitors: multiple actions | 2.2 | 13 | Citations (PDF) |
| 222 | Coronary Artery Bypass Grafting Combined with Open Versus Endovascular Abdominal Aortic Aneurysm Repair | 1.2 | 1 | Citations (PDF) |
| 223 | C-reactive protein levels and aortic aneurysmal disease progression after endovascular repair: The jury is still out | 2.2 | 1 | Citations (PDF) |
| 224 | Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate | 7.4 | 67 | Citations (PDF) |
| 225 | Impact of comorbidity on outcome in kidney transplant recipients: a retrospective study in Italy | 2.5 | 7 | Citations (PDF) |
| 226 | A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients | 9.0 | 21 | Citations (PDF) |
| 227 | The Relation Between Atherosclerosis and the Neutrophil–Lymphocyte Ratio | 1.8 | 280 | Citations (PDF) |
| 228 | Definition of Best Medical Treatment in Asymptomatic and Symptomatic Carotid Artery Stenosis | 2.0 | 64 | Citations (PDF) |
| 229 | Does bilirubin protect against developing diabetes mellitus? | 2.6 | 4 | Citations (PDF) |
| 230 | Critical Issues and Controversies in the Management of Patients With Carotid Artery Stenosis | 2.0 | 3 | Citations (PDF) |
| 231 | The effect of bergamot on dyslipidemia | 7.4 | 39 | Citations (PDF) |
| 232 | Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis | 9.0 | 57 | Citations (PDF) |
| 233 | Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus | 2.0 | 67 | Citations (PDF) |
| 234 | High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practice | 2.6 | 9 | Citations (PDF) |
| 235 | Statins and non-alcoholic steatohepatitis | 2.9 | 9 | Citations (PDF) |
| 236 | Adherence to statin treatment: an important issue in clinical practice | 2.2 | 1 | Citations (PDF) |
| 237 | Statins and Type 2 Diabetes Mellitus: An Update After 1 Year | 2.3 | 9 | Citations (PDF) |
| 238 | Lipids, Statins and Heart Failure: An Update | 2.3 | 20 | Citations (PDF) |
| 239 | Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk? | 1.4 | 54 | Citations (PDF) |
| 240 | Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies | 7.4 | 179 | Citations (PDF) |
| 241 | A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations | 3.7 | 149 | Citations (PDF) |
| 242 | Erectile dysfunction and coronary heart disease | 1.8 | 36 | Citations (PDF) |
| 243 | Association between statin use and plasma D-dimer levels | 4.4 | 139 | Citations (PDF) |
| 244 | Letter to the Editor Dysfunctional high-density lipoprotein: not only quantity but first of all quality? | 1.2 | 6 | Citations (PDF) |
| 245 | Ear lobe crease: a marker of coronary artery disease? | 1.2 | 26 | Citations (PDF) |
| 246 | Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update | 4.7 | 118 | Citations (PDF) |
| 247 | Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome | 4.7 | 134 | Citations (PDF) |
| 248 | Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel | 1.2 | 308 | Citations (PDF) |
| 249 | All for Statins and Statins for All; An Update | 2.3 | 20 | Citations (PDF) |
| 250 | Effects of oral hypoglycemic agents on platelet function | 2.6 | 22 | Citations (PDF) |
| 251 | A possible relationship between renal impairment and complications development in type 2 diabetes mellitus: a prospective, observational study in Italy | 2.6 | 4 | Citations (PDF) |
| 252 | Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials | 1.2 | 148 | Citations (PDF) |
| 253 | Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? | 2.3 | 41 | Citations (PDF) |
| 254 | How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic | 2.2 | 23 | Citations (PDF) |
| 255 | Endocan and Atherosclerosis | 2.0 | 17 | Citations (PDF) |
| 256 | Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease | 4.1 | 20 | Citations (PDF) |
| 257 | Effects of Coenzyme Q10 on Statin-Induced Myopathy | 2.6 | 162 | Citations (PDF) |
| 258 | New-Onset Diabetes and Statins: Throw the Bath Water Out, But, Please, Keep the Baby! | 5.0 | 23 | Citations (PDF) |
| 259 | All-cause mortality and estimated renal function in type 2 diabetes mellitus outpatients: Is there a relationship with the equation used? | 2.8 | 11 | Citations (PDF) |
| 260 | Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials | 9.0 | 150 | Citations (PDF) |
| 261 | Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients | 1.2 | 48 | Citations (PDF) |
| 262 | Mean platelet volume in patients undergoing percutaneous coronary intervention | 2.5 | 6 | Citations (PDF) |
| 263 | In reply—Coenzyme Q10 and Statin-Induced Myopathy | 2.6 | 8 | Citations (PDF) |
| 264 | Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors — Results from a systematic review and meta-analysis of randomized controlled trials | 2.2 | 148 | Citations (PDF) |
| 265 | Strategies to overcome statin intolerance | 2.8 | 12 | Citations (PDF) |
| 266 | Platelets and diabetes: A complex association | 2.5 | 6 | Citations (PDF) |
| 267 | Statins and Niacin: The End of Residual Risk Therapy? 2015, , 37-43 | | 2 | Citations (PDF) |
| 268 | The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation | 1.2 | 607 | Citations (PDF) |
| 269 | Abdominal aortic aneurysms and diabetes mellitus | 2.6 | 44 | Citations (PDF) |
| 270 | Should we consider ezetimibe to reach even lower LDL-C targets? | 2.2 | 3 | Citations (PDF) |
| 271 | Endocan: A novel inflammatory indicator in cardiovascular disease? | 1.2 | 162 | Citations (PDF) |
| 272 | Metabolic syndrome: Different definitions and gender-specific associations with cardiovascular risk factors | 2.8 | 3 | Citations (PDF) |
| 273 | Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom? 2015, , 179-190 | | 1 | Citations (PDF) |
| 274 | Contrast-Induced Nephropathy | 2.0 | 93 | Citations (PDF) |
| 275 | Analysis of vitamin D levels in patients with and without statin-associated myalgia — A systematic review and meta-analysis of 7 studies with 2420 patients | 2.2 | 151 | Citations (PDF) |
| 276 | Do We Need Guideline-Driven Specific Lipid Goals to Achieve Regression of Coronary Atherosclerosis and Maximize Therapy Benefits? | 1.9 | 0 | Citations (PDF) |
| 277 | Statin therapy and cardiovascular outcomes after coronary revascularization in the elderly | 1.2 | 3 | Citations (PDF) |
| 278 | High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus | 2.6 | 13 | Citations (PDF) |
| 279 | Genetic, epidemiologic and clinical data strongly suggest that fasting or non-fasting triglycerides are independent cardiovascular risk factors | 2.2 | 4 | Citations (PDF) |
| 280 | Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention | 2.2 | 8 | Citations (PDF) |
| 281 | Statins and Fibrates: Should They Be Recommended? 2015, , 11-23 | | 1 | Citations (PDF) |
| 282 | Preface: | 1.4 | 0 | Citations (PDF) |
| 283 | Editorial: Statin Potency, LDL Receptors and New Onset Diabetes | 1.4 | 6 | Citations (PDF) |
| 284 | 18F-Fluorodeoxyglucose Uptake in Abdominal Aortic Aneurysms: A Useful Biomarker of AAA Rupture Risk | 2.7 | 3 | Citations (PDF) |
| 285 | Editorial: Ageing, Longevity, Exceptional Longevity and Related Genetic and Non Genetics Markers: Panel Statement | 1.4 | 46 | Citations (PDF) |
| 286 | Editorial (Thematic Issue: Novel Data on the Pathogenesis of Atherosclerosis, Treatment Targets, and New Therapeutic Interventions in Lipid-Related Cardiovascular Risk Factors) | 2.3 | 2 | Citations (PDF) |
| 287 | Editorial (Thematic Issues: Managing the Cardiovascular Risk Associated with the Metabolic Syndrome) | 2.3 | 1 | Citations (PDF) |
| 288 | Are statins ‘IDEAL’ for non-alcoholic fatty liver disease? | 2.2 | 20 | Citations (PDF) |
| 289 | Reaching hypertriglyceridemia goals | 2.2 | 0 | Citations (PDF) |
| 290 | Risk of illness, hospitalization and death in a cohort of blood donors in Italy | 2.2 | 9 | Citations (PDF) |
| 291 | Should we expand the concept of coronary heart disease equivalents? | 1.8 | 49 | Citations (PDF) |
| 292 | Subclinical Cushing's syndrome and cardiovascular disease | 22.3 | 8 | Citations (PDF) |
| 293 | Caloric and fat intake in statin users | 10.6 | 2 | Citations (PDF) |
| 294 | ETC-1002: A future option for lipid disorders? | 1.2 | 34 | Citations (PDF) |
| 295 | Peripheral artery disease in patients with type 2 diabetes | 2.6 | 3 | Citations (PDF) |
| 296 | Endocan—A Novel Inflammatory Indicator in Newly Diagnosed Patients With Hypertension | 2.0 | 128 | Citations (PDF) |
| 297 | The Effects of Anti-Diabetic Drugs on LDL Subclasses: Any Role for Colesevelam? | 2.2 | 0 | Citations (PDF) |
| 298 | Bilirubin Levels and Their Association with Carotid Intima Media Thickness and High-Sensitivity C-reactive Protein in Patients with Psoriasis Vulgaris | 7.5 | 32 | Citations (PDF) |
| 299 | Regarding “Progression of asymptomatic carotid stenosis despite optimal medical therapy” | 1.6 | 4 | Citations (PDF) |
| 300 | Implications of the timely diagnosis of lower extremity peripheral arterial disease | 2.2 | 0 | Citations (PDF) |
| 301 | Uric acid, chronic kidney disease and type 2 diabetes: A cluster of vascular risk factors | 2.6 | 13 | Citations (PDF) |
| 302 | Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness | 2.4 | 72 | Citations (PDF) |
| 303 | The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps! | 2.2 | 9 | Citations (PDF) |
| 304 | The effects of antiepileptic drugs on vascular risk factors: A narrative review | 2.3 | 68 | Citations (PDF) |
| 305 | Serum endocan levels as a marker of disease activity in patients with Behçet disease | 1.3 | 112 | Citations (PDF) |
| 306 | The Role of Statins in the Treatment of Type 2 Diabetes Mellitus: An Update | 2.3 | 36 | Citations (PDF) |
| 307 | Metabolic Syndrome and Non-Cardiac Vascular Diseases: An Update from Human Studies | 2.3 | 44 | Citations (PDF) |
| 308 | Psoriasis and Vascular Risk: An Update | 2.3 | 19 | Citations (PDF) |
| 309 | Combination of Statin Plus Renin Angiotensin System Inhibition for the Prevention or the Treatment of Atherosclerotic Cardiovascular Disease | 2.3 | 21 | Citations (PDF) |
| 310 | Hypolipidaemic Drug Treatment: Yesterday is Not Gone Yet, Today is Challenging and Tomorrow is Coming Soon; let us Combine them all | 2.3 | 9 | Citations (PDF) |
| 311 | Hemostatic Factors and the Metabolic Syndrome | 1.4 | 38 | Citations (PDF) |
| 312 | Effect of Rosuvastatin on Non-alcoholic Steatohepatitis in Patients with Metabolic Syndrome and Hypercholesterolaemia: A Preliminary Report | 1.4 | 36 | Citations (PDF) |
| 313 | Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview | 1.4 | 48 | Citations (PDF) |
| 314 | Ageing Mechanisms and Associated Lipid Changes | 1.4 | 14 | Citations (PDF) |
| 315 | The Challenges in Moving from Ageing to Successful Longevity | 1.4 | 17 | Citations (PDF) |
| 316 | Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome | 1.4 | 16 | Citations (PDF) |
| 317 | Angiotensin II Increases Corpus Cavernosal Contractility and Oxidative Stress in Partial Bladder Outlet Obstructed Rabbits: Relevance to Erectile Dysfunction | 0.4 | 3 | Citations (PDF) |
| 318 | The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy – 5-year follow-up | 3.8 | 27 | Citations (PDF) |
| 319 | Signaling mechanisms of a water soluble curcumin derivative in experimental type 1 diabetes with cardiomyopathy | 3.6 | 46 | Citations (PDF) |
| 320 | Statins and nonalcoholic fatty liver disease: a bright future? | 4.1 | 10 | Citations (PDF) |
| 321 | Renal dysfunction and all-cause mortality in cardio-renal syndrome: Calculation of glomerular filtration rate is crucial, independent of the equation | 2.2 | 2 | Citations (PDF) |
| 322 | A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? | 2.2 | 68 | Citations (PDF) |
| 323 | 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? | 5.0 | 83 | Citations (PDF) |
| 324 | Summarizing the FIELD study: lessons from a ‘negative' trial | 2.3 | 9 | Citations (PDF) |
| 325 | The effect of biological age on the metabolic responsiveness of mice fed a high-fat diet | 1.4 | 12 | Citations (PDF) |
| 326 | The effects of statins on blood pressure in normotensive or hypertensive subjects — A meta-analysis of randomized controlled trials | 2.2 | 36 | Citations (PDF) |
| 327 | Alcohol consumption and the heart | 2.2 | 1 | Citations (PDF) |
| 328 | Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review | 2.2 | 77 | Citations (PDF) |
| 329 | Metabolic syndrome and renal disease | 2.2 | 76 | Citations (PDF) |
| 330 | Statins: A sine qua non of the management of patients with abdominal aortic aneurysms | 2.2 | 4 | Citations (PDF) |
| 331 | Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—A meta-analysis of 11 randomized controlled trials involving 21,295 participants | 9.0 | 84 | Citations (PDF) |
| 332 | Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity | 2.0 | 1 | Citations (PDF) |
| 333 | Comment to “Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property” | 1.3 | 0 | Citations (PDF) |
| 334 | Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials | 2.2 | 35 | Citations (PDF) |
| 335 | Why Calls for More Routine Carotid Stenting Are Currently Inappropriate | 6.2 | 47 | Citations (PDF) |
| 336 | Additional Issues on Screening, Prevention, and Treatment of Abdominal Aortic Aneurysms | 2.0 | 2 | Citations (PDF) |
| 337 | Epicardial fat and vascular risk | 1.8 | 66 | Citations (PDF) |
| 338 | Association Between Epicardial Fat Thickness and Weight Homeostasis Hormones in Patients With Noncachectic Heart Failure | 2.0 | 19 | Citations (PDF) |
| 339 | Statins and Venous Thromboembolism | 2.0 | 8 | Citations (PDF) |
| 340 | Omega-3 fatty acids for the treatment of nonalcoholic fatty liver disease in children and adolescents | 1.0 | 0 | Citations (PDF) |
| 341 | Platelet cholesterol: From man to seal | 2.5 | 0 | Citations (PDF) |
| 342 | New therapies to reduce low-density lipoprotein cholesterol | 1.8 | 20 | Citations (PDF) |
| 343 | Statin therapy and new-onset diabetes: an attempt at recommendations | 3.3 | 9 | Citations (PDF) |
| 344 | Cardiovascular Risk Assessment in Diabetes Mellitus | 2.0 | 21 | Citations (PDF) |
| 345 | Response to Red Blood Cell Distribution Width Is a Predictor of Readmission in Cardiac Patients | 2.1 | 4 | Citations (PDF) |
| 346 | Perioperative/Periprocedural Effects of Statin Treatment for Patients Undergoing Vascular Surgery or Endovascular Procedures: An Update | 1.4 | 28 | Citations (PDF) |
| 347 | Statins and Infrainguinal Vascular Bypass Procedures | 1.4 | 13 | Citations (PDF) |
| 348 | Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study | 1.2 | 20 | Citations (PDF) |
| 349 | Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An Update) | 2.3 | 0 | Citations (PDF) |
| 350 | Editorial (Diabetes, Obesity and Vascular Disease - An Update) | 2.3 | 8 | Citations (PDF) |
| 351 | The Role of Fibrate Treatment in Dyslipidemia: An Overview | 2.3 | 106 | Citations (PDF) |
| 352 | Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches | 4.6 | 122 | Citations (PDF) |
| 353 | Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study | 1.2 | 36 | Citations (PDF) |
| 354 | Subclinical hypothyroidism and vascular risk: Αn update | 2.0 | 29 | Citations (PDF) |
| 355 | PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders? | 2.3 | 46 | Citations (PDF) |
| 356 | Short-term statin therapy for prevention of contrast-induced AKI | 13.6 | 23 | Citations (PDF) |
| 357 | New statin guidelines and promising novel therapeutics | 12.5 | 22 | Citations (PDF) |
| 358 | Colesevelam: A New and Improved Bile Acid Sequestrant? | 2.3 | 17 | Citations (PDF) |
| 359 | Uric Acid and Diabetes: Is there a Link? | 2.3 | 83 | Citations (PDF) |
| 360 | A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin | 2.3 | 21 | Citations (PDF) |
| 361 | Microalbuminuria: A Neglected Cardiovascular Risk Factor in Non-diabetic Individuals? | 2.3 | 11 | Citations (PDF) |
| 362 | Pioglitazone and Cancer: Angel or Demon? | 2.3 | 30 | Citations (PDF) |
| 363 | Ezetimibe Therapy for Dyslipidemia: An Update | 2.3 | 40 | Citations (PDF) |
| 364 | Hydrochlorothiazide vs. Chlorthalidone as the Optimal Diuretic for the Management of Hypertension | 2.3 | 8 | Citations (PDF) |
| 365 | Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia? | 2.3 | 39 | Citations (PDF) |
| 366 | The Impact of Smoking on Cardiovascular Outcomes and Comorbidities in Statin-treated Patients with Coronary Artery Disease: A Post hoc Analysis of the GREACE Study | 1.4 | 20 | Citations (PDF) |
| 367 | Drug Treatment of Combined Hyperlipidemia | 2.6 | 12 | Citations (PDF) |
| 368 | Orlistat-Associated Adverse Effects and Drug Interactions | 3.2 | 307 | Citations (PDF) |
| 369 | Why the United States Center for Medicare and Medicaid Services should not extend reimbursement indications for carotid artery angioplasty/stenting | 1.2 | 2 | Citations (PDF) |
| 370 | Statins and new-onset diabetes mellitus—a matter for debate | 10.6 | 25 | Citations (PDF) |
| 371 | Long-Term Impact of Multifactorial Treatment on New-Onset Diabetes and Related Cardiovascular Events in Metabolic Syndrome | 2.0 | 26 | Citations (PDF) |
| 372 | Triglycerides | 1.8 | 33 | Citations (PDF) |
| 373 | Statins and noncardiac vascular disease | 1.8 | 22 | Citations (PDF) |
| 374 | Fibrinogen, Hematocrit, and Platelets in Mild Kidney Dysfunction and the Role of Uric Acid: An Italian Male Population Study | 1.8 | 0 | Citations (PDF) |
| 375 | Lipid Lowering Agents and the Endothelium: An Update after 4 Years | 1.4 | 16 | Citations (PDF) |
| 376 | Dronedarone: An overview | 3.9 | 22 | Citations (PDF) |
| 377 | Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome | 2.3 | 5 | Citations (PDF) |
| 378 | Adding Ezetimibe to Statin Treatment: is LDL-C Lowering the Only benefit? | 1.0 | 3 | Citations (PDF) |
| 379 | Obstructive Sleep Apnea and Cardiovascular Risk | 2.0 | 15 | Citations (PDF) |
| 380 | Local Versus General Anesthesia for Carotid Endarterectomy | 2.0 | 10 | Citations (PDF) |
| 381 | Stage of chronic kidney disease and severity of coronary heart disease manifestation | 2.3 | 14 | Citations (PDF) |
| 382 | Therapeutic options for statin-intolerant patients | 2.2 | 4 | Citations (PDF) |
| 383 | Effect of Atorvastatin Monotherapy and Low-Dose Atorvastatin/Ezetimibe Combination on Fasting and Postprandial Triglycerides in Combined Hyperlipidemia | 2.8 | 5 | Citations (PDF) |
| 384 | Near-Infrared Spectroscopy Assessment Following Exercise Training in Patients With Intermittent Claudication and in Untrained Healthy Participants | 0.7 | 46 | Citations (PDF) |
| 385 | Prevalence of Metabolic Syndrome According to Different Definitions in a Hypertensive Population | 2.0 | 17 | Citations (PDF) |
| 386 | Estimated Glomerular Filtration rate (eGFR): A Serum Creatinine-Based Test for the Detection of Chronic Kidney Disease and its Impact on Clinical Practice | 1.2 | 1 | Citations (PDF) |
| 387 | Editorial (Should Chronic Kidney Disease be Considered as a Coronary Heart Disease Equivalent?) | 1.4 | 21 | Citations (PDF) |
| 388 | Hypertriglyceridemia-induced acute pancreatitis: clinical considerations | 1.0 | 2 | Citations (PDF) |
| 389 | Lipids and Non-Cardiac Vascular Disease: A Lecture Overview | 1.4 | 2 | Citations (PDF) |
| 390 | Should raising high-density lipoprotein cholesterol be a matter of debate? | 1.2 | 14 | Citations (PDF) |
| 391 | An update on biomarkers of heart failure in hypertensive patients | 1.2 | 44 | Citations (PDF) |
| 392 | Ezetimibe – a new approach in hypercholesterolemia management | 3.6 | 6 | Citations (PDF) |
| 393 | Welcome to CMRO’s 40th Anniversary Issue | 2.2 | 40 | Citations (PDF) |
| 394 | Effect of Antiplatelet Agents, Statins, and Other Drugs on Vascular Access Patency Rates | 2.0 | 7 | Citations (PDF) |
| 395 | Clinical benefits of ezetimibe use: is absence of proof, proof of absence? | 2.3 | 15 | Citations (PDF) |
| 396 | Relation of Improvement in Glomerular Filtration Rate With Atorvastatin to Reductions in Heart Failure Morbidity | 1.9 | 7 | Citations (PDF) |
| 397 | Smoking and non-alcoholic steatohepatitis (NASH): The GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial | 2.9 | 5 | Citations (PDF) |
| 398 | Comparison of the five 2011 guidelines for the treatment of carotid stenosis | 1.6 | 47 | Citations (PDF) |
| 399 | The meaning of hypokalemia in heart failure | 2.2 | 56 | Citations (PDF) |
| 400 | Carotid artery stenting: “Good news” or “bad news” for post-procedural cognitive function? | 2.2 | 0 | Citations (PDF) |
| 401 | Role of Antihypertensive Drugs in Arterial ‘De-Stiffening’ and Central Pulsatile Hemodynamics | 2.6 | 50 | Citations (PDF) |
| 402 | Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance | 2.0 | 3 | Citations (PDF) |
| 403 | Heparin and platelet activation | 2.4 | 0 | Citations (PDF) |
| 404 | Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease? | 14.1 | 181 | Citations (PDF) |
| 405 | Metformin and heart failure: never say never again | 2.3 | 25 | Citations (PDF) |
| 406 | Regarding “Estimating the risk of solid organ malignancy in patients undergoing routine computed tomography scans after endovascular aneurysm repair” | 1.6 | 1 | Citations (PDF) |
| 407 | Statins and Infrainguinal Vascular Bypass Procedures | 1.4 | 1 | Citations (PDF) |
| 408 | Perioperative/Periprocedural Effects of Statin Treatment for Patients Undergoing Vascular Surgery or Endovascular Procedures: An Update | 1.4 | 12 | Citations (PDF) |
| 409 | Editorial: [Aliskiren/Amlodipine Single-Pill Combinations: More Evidence in Favour of Combination Formulations for the Treatment of Hypertension] | 1.4 | 1 | Citations (PDF) |
| 410 | Water Soluble Vitamin E Administration in Wistar Rats with Non-alcoholic Fatty Liver Disease | 0.2 | 11 | Citations (PDF) |
| 411 | State of the art paper The role of G protein coupled receptor kinases in neurocardiovascular pathophysiology | 1.2 | 5 | Citations (PDF) |
| 412 | Editorial [ Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough? ] | 1.4 | 10 | Citations (PDF) |
| 413 | Editorial Lipid-lowering therapies and achievement of LDL-cholesterol targets | 1.2 | 16 | Citations (PDF) |
| 414 | Editorial The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings | 1.2 | 3 | Citations (PDF) |
| 415 | Letter to the Editor Obstructive sleep apnoea syndrome and cardiovascular risk | 1.2 | 18 | Citations (PDF) |
| 416 | Targeting cardiovascular risk: the impact of age, gender and compliance to treatment | 2.2 | 5 | Citations (PDF) |
| 417 | Why the United States Center for Medicare and Medicaid Services (CMS) should not extend reimbursement indications for carotid artery angioplasty/stenting | 2.5 | 4 | Citations (PDF) |
| 418 | Response to Mildly Decreased Glomerular Filtration Rate Is Associated With Poor Coronary Heart Disease Outcome | 2.1 | 2 | Citations (PDF) |
| 419 | Mechanisms Linking Nonalcoholic Fatty Liver Disease with Coronary Artery Disease | 2.2 | 8 | Citations (PDF) |
| 420 | Lipoprotein alterations and reduced growth hormone secretion: relationships with obesity and cardiovascular risk<sup>1</sup> | 2.5 | 8 | Citations (PDF) |
| 421 | Statins in Patients With Renal Dysfunction | 1.9 | 7 | Citations (PDF) |
| 422 | In-hospital mortality for pulmonary embolism: relationship with chronic kidney disease and end-stage renal disease. The hospital admission and discharge database of the Emilia Romagna region of Italy | 2.5 | 28 | Citations (PDF) |
| 423 | Gender and Socio-economic Differences in Daily Smoking and Smoking Cessation Among Adult Residents in a Greek Rural Area | 0.2 | 11 | Citations (PDF) |
| 424 | Weekend Versus Weekday, Morning Versus Evening Admission in Relationship to Mortality in Acute Coronary Syndrome Patients in 6 Middle Eastern Countries: Results from Gulf Race 2 Registry | 0.2 | 6 | Citations (PDF) |
| 425 | Patient with Hypertriglyceridemia, Type 2 Diabetes, and Chronic Kidney Disease Treated with Atorvastatin and Omega-3 Fatty Acid Ethyl Esters | 0.2 | 4 | Citations (PDF) |
| 426 | The Role of Psychobiological and Neuroendocrine Mechanisms in Appetite Regulation and Obesity | 0.2 | 18 | Citations (PDF) |
| 427 | Letter to Editor: Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome | 1.2 | 1 | Citations (PDF) |
| 428 | The role of ezetimibe in LDL cholesterol goal attainment in very high risk patients | 2.2 | 0 | Citations (PDF) |
| 429 | Prevalence of low high-density lipoprotein cholesterol (HDL-C) as a marker of residual cardiovascular risk among acute coronary syndrome patients from Oman | 2.2 | 10 | Citations (PDF) |
| 430 | Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study | 2.2 | 42 | Citations (PDF) |
| 431 | Ezetimibe and low density lipoprotein subfractions: an ongoing debate | 2.2 | 11 | Citations (PDF) |
| 432 | Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? | 3.9 | 35 | Citations (PDF) |
| 433 | The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia | 2.3 | 27 | Citations (PDF) |
| 434 | Is the Risk for Cardiovascular Disease Increased in all Phenotypes of the Polycystic Ovary Syndrome? | 2.0 | 9 | Citations (PDF) |
| 435 | Comparative efficacy of the addition of ezetimibe to statin<i>vs</i>statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis | 2.2 | 71 | Citations (PDF) |
| 436 | Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? | 2.3 | 33 | Citations (PDF) |
| 437 | Peroxisome Proliferator-Activated Receptors and Atherosclerosis | 2.0 | 31 | Citations (PDF) |
| 438 | Acute pancreatitis in pregnancy: an overview | 1.0 | 83 | Citations (PDF) |
| 439 | Statins and contrast-induced nephropathy: Issues requiring further investigation | 2.2 | 4 | Citations (PDF) |
| 440 | Optimal statin type and dosage for vascular patients | 1.6 | 27 | Citations (PDF) |
| 441 | Reply | 1.6 | 0 | Citations (PDF) |
| 442 | Carotid artery stenting may be contraindicated in female patients with symptomatic carotid artery stenosis | 1.6 | 0 | Citations (PDF) |
| 443 | Nutrition During Pregnancy and the Effect of Carbohydrates on the Offspring’s Metabolic Profile: In Search of the “Perfect Maternal Diet” | 0.2 | 40 | Citations (PDF) |
| 444 | Effect of Angiotensin II and its Receptor Antagonists on Human Corpus Cavernous Contractility and Oxidative Stress: Modulation of Nitric Oxide Mediated Relaxation | 4.4 | 16 | Citations (PDF) |
| 445 | Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: A systematic review and metaanalysis | 1.2 | 28 | Citations (PDF) |
| 446 | Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver | 1.8 | 41 | Citations (PDF) |
| 447 | Best medical treatment for a symptomatic carotid artery stenosis | 35.3 | 3 | Citations (PDF) |
| 448 | Raised liver enzymes in patients taking statins – Authors' reply | 35.3 | 1 | Citations (PDF) |
| 449 | Dyslipidemia Induced by Drugs Used for the Prevention and Treatment of Vascular Diseases | 0.2 | 13 | Citations (PDF) |
| 450 | Dyslipidaemia of Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: the Case for Residual Risk Reduction After Statin Treatment | 0.2 | 52 | Citations (PDF) |
| 451 | Editorial Assessing renal function – searching for the perfect marker continues! | 1.2 | 13 | Citations (PDF) |
| 452 | State of the art papers Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment? | 1.2 | 9 | Citations (PDF) |
| 453 | Prevalence, Predictors, and Impact of Low High-Density Lipoprotein Cholesterol on in-Hospital Outcomes Among Acute Coronary Syndrome Patients in the Middle East | 0.2 | 13 | Citations (PDF) |
| 454 | IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis | 1.2 | 42 | Citations (PDF) |
| 455 | Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study | 1.2 | 68 | Citations (PDF) |
| 456 | Regulation of Inducible Nitric Oxide Synthase (iNOS) and its Potential Role in Insulin Resistance, Diabetes and Heart Failure | 0.2 | 126 | Citations (PDF) |
| 457 | Ideal lipid profile and genes for an extended life span | 1.8 | 11 | Citations (PDF) |
| 458 | Left atrial size in hypertension and stroke | 1.2 | 35 | Citations (PDF) |
| 459 | Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels | 1.2 | 23 | Citations (PDF) |
| 460 | Pulmonary arterial hypertension and statins: an update | 1.8 | 17 | Citations (PDF) |
| 461 | Editorial [Hot Topic: New Developments in the Prevention and Treatment of Vascular Disease - 2 Executive (Guest Editors: Manfredi Rizzo and Dimitri P. Mikhailidis)] | 2.3 | 23 | Citations (PDF) |
| 462 | Editorial [Carotid Intima-Media Thickness and Ezetimibe: The End of a Misunderstanding?] | 1.4 | 16 | Citations (PDF) |
| 463 | Gender Differences in the Treatment of Ischemic Heart Disease | 2.3 | 10 | Citations (PDF) |
| 464 | Diagnostic Value of Postprandial Triglyceride Testing in Healthy Subjects:A Meta-Analysis | 1.4 | 98 | Citations (PDF) |
| 465 | Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome | 2.3 | 19 | Citations (PDF) |
| 466 | Definition of Postprandial Lipaemia | 1.4 | 43 | Citations (PDF) |
| 467 | Proposing a “Lipemic Index” As a Nutritional and Research Tool | 1.4 | 7 | Citations (PDF) |
| 468 | Lipid Lowering Drugs and Gallstones: A Therapeutic Option? | 2.3 | 18 | Citations (PDF) |
| 469 | Ezetimibe; More Than a Low Density Lipoprotein Cholesterol Lowering Drug? An Update After 4 Years | 1.4 | 28 | Citations (PDF) |
| 470 | &#x201C;European Panel On Low Density Lipoprotein (LDL) Subclasses&#x201D;: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses: Executive Summary | 1.4 | 103 | Citations (PDF) |
| 471 | Postprandial Lipemia in Children and Adolescents | 1.4 | 6 | Citations (PDF) |
| 472 | Alanine Aminotransferase Is Associated With Metabolic Syndrome Independently of Insulin Resistance | 1.8 | 2 | Citations (PDF) |
| 473 | Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients | 4.2 | 116 | Citations (PDF) |
| 474 | Correlation of the severity of diabetic retinopathy and the heart muscle perfusion in patients with type 2 diabetes | 2.6 | 7 | Citations (PDF) |
| 475 | Impact of Ezetimibe Coadministered With Statins on Cardiovascular Events Following Acute Coronary Syndrome: A 3-Year Population-Based Retrospective Cohort Study in Taiwan | 2.9 | 2 | Citations (PDF) |
| 476 | Impact of Statins on Glucose Metabolism—A Matter of Debate | 1.9 | 4 | Citations (PDF) |
| 477 | Screening for peripheral artery disease in dialysis patients: an opportunity for early disease detection and timely initiation of appropriate therapeutic measures | 1.5 | 7 | Citations (PDF) |
| 478 | Molecular markers and bladder carcinoma: Schistosomal and non-schistosomal | 1.8 | 5 | Citations (PDF) |
| 479 | Relationships of osteoprotegerin with albuminuria and asymmetric dimethylarginine in essential hypertension: integrating vascular dysfunction | 3.9 | 7 | Citations (PDF) |
| 480 | The DEFINE study: a bright future for CETP inhibitors? | 4.1 | 4 | Citations (PDF) |
| 481 | Current treatment for nonalcoholic fatty liver disease | 2.3 | 2 | Citations (PDF) |
| 482 | Mean Platelet Volume: A Link Between Thrombosis and Inflammation? | 2.3 | 977 | Citations (PDF) |
| 483 | &#x201C;European Panel on Low Density Lipoprotein (LDL) Subclasses&#x201D;: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses | 1.4 | 176 | Citations (PDF) |
| 484 | Glycated hemoglobin A<sub>1c</sub>(HbA<sub>1c</sub>) and diabetes: a new era? | 2.2 | 5 | Citations (PDF) |
| 485 | Does Metabolic Syndrome Influence Outcome Following Percutaneous Coronary Intervention? | 2.0 | 2 | Citations (PDF) |
| 486 | Carotid Artery Stenosis and Heart Valve Surgery: A Complex Scenario | 2.0 | 0 | Citations (PDF) |
| 487 | Review: Antiplatelet Drugs: What Comes Next? | 1.8 | 17 | Citations (PDF) |
| 488 | The Rationale for Lowering the Size Threshold in Elective Endovascular Repair of Abdominal Aortic Aneurysm | 1.7 | 18 | Citations (PDF) |
| 489 | A New Rapid Method to Measure Human Platelet Cholesterol | 1.8 | 5 | Citations (PDF) |
| 490 | Peripheral Arterial Disease and HIV-Positive Patients | 2.0 | 6 | Citations (PDF) |
| 491 | Passive Smoking: The Democratic Right of Nonsmokers to Survive | 2.0 | 7 | Citations (PDF) |
| 492 | Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target? | 2.3 | 24 | Citations (PDF) |
| 493 | Letter by Paraskevas et al Regarding Article, “Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association” | 6.2 | 1 | Citations (PDF) |
| 494 | Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: ‘A new kid on the block’? | 3.9 | 22 | Citations (PDF) |
| 495 | Aging Men and Lipids | 2.0 | 17 | Citations (PDF) |
| 496 | Point of care testing is appropriate for National Health Service health check | 1.8 | 20 | Citations (PDF) |
| 497 | Optimal contemporary management of symptomatic and asymptomatic carotid artery stenosis | 1.2 | 16 | Citations (PDF) |
| 498 | Erythropoietin update 2011 | 1.3 | 10 | Citations (PDF) |
| 499 | Pleiotropic Effects of Nicotinic Acid: Beyond High Density Lipoprotein Cholesterol Elevation | 1.4 | 28 | Citations (PDF) |
| 500 | Rectus Sheath Hematoma: A Simplified Emergency Surgical Approach | 0.2 | 11 | Citations (PDF) |
| 501 | Effects of Improving Glycemic Control with Insulin on Leptin, Adiponectin, Ghrelin and Neuropeptidey Levels in Patients with Type 2 Diabetes Mellitus: a Pilot Study | 0.2 | 15 | Citations (PDF) |
| 502 | Assessment and Clinical Relevance of Non-Fasting and Postprandial Triglycerides: An Expert Panel Statement | 1.4 | 3 | Citations (PDF) |
| 503 | Epidemiology and Pathophysiology of Carotid Artery Disease 2011, , 1-7 | | 0 | Citations (PDF) |
| 504 | Effect of Non-Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemia | 1.4 | 25 | Citations (PDF) |
| 505 | Diabetes and Antioxidants: Myth or Reality? | 1.4 | 21 | Citations (PDF) |
| 506 | The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis | 1.4 | 13 | Citations (PDF) |
| 507 | Should Adipokines be Considered in the Choice of the Treatment of Obesity-Related Health Problems? | 2.0 | 90 | Citations (PDF) |
| 508 | Vitamin D and Metabolic Syndrome: Is There a Link? | 2.3 | 34 | Citations (PDF) |
| 509 | Chronic Hepatitis C, Insulin Resistance and Vascular Disease | 2.3 | 4 | Citations (PDF) |
| 510 | ESVS Guidelines: Section B - Diagnosis and Investigation of Patients with Carotid Stenosis | 1.4 | 12 | Citations (PDF) |
| 511 | ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis | 1.4 | 34 | Citations (PDF) |
| 512 | The Estrogenic Burden on Vascular Risk in Male-to-Female Transsexuals | 2.3 | 10 | Citations (PDF) |
| 513 | Preventing Type 2 Diabetes Mellitus: Room for Residual Risk Reduction After Lifestyle Changes? | 2.3 | 9 | Citations (PDF) |
| 514 | The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification | 1.8 | 25 | Citations (PDF) |
| 515 | Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association? | 1.8 | 21 | Citations (PDF) |
| 516 | Obesity and Arterial Compliance Alterations | 1.4 | 53 | Citations (PDF) |
| 517 | Effects of l-Canavanine and ozone on vascular reactivity in septicemic rats | 3.6 | 1 | Citations (PDF) |
| 518 | Statin use in patients with chronic kidney disease stages 2–4: targeting beyond improved mortality rates | 1.5 | 5 | Citations (PDF) |
| 519 | Cardiovascular events in chronic dialysis patients: emphasizing the importance of vascular disease prevention | 1.5 | 18 | Citations (PDF) |
| 520 | Editorial Are we getting to lipid targets in real life? | 1.2 | 17 | Citations (PDF) |
| 521 | Editorial [Concurrent Blood Pressure, Glycemic and Lipid Control for the Prevention of Vascular Complications of Type II Diabetes Mellitus: A Long Overdue Objective?] | 1.4 | 4 | Citations (PDF) |
| 522 | Visfatin/PBEF and Atherosclerosis-Related Diseases | 1.4 | 62 | Citations (PDF) |
| 523 | Interpreting the Carotid Revascularization Endarterectomy Versus Stent Trial (CREST): Additional Trials Are Needed | 1.2 | 2 | Citations (PDF) |
| 524 | eComment: Endovascular repair of ruptured abdominal aortic aneurysms: identifying issues which may be difficult to achieve | 1.5 | 1 | Citations (PDF) |
| 525 | Cardiovascular Risk Factors and Estimated 10-Year Risk of Fatal Cardiovascular Events Using Various Equations in Greeks With Metabolic Syndrome | 2.0 | 12 | Citations (PDF) |
| 526 | Are Symptomatic Patients Appropriate Candidates For Carotid Artery Stenting? No (at Least Not At Present) | 1.2 | 4 | Citations (PDF) |
| 527 | Radial Artery Catheterization for Percutaneous Vascular or Coronary Interventions: An Innocent Procedure? | 2.0 | 15 | Citations (PDF) |
| 528 | Predictors of Abdominal Aortic Aneurysm (AAA) Growth and AAA Rupture Risk Besides AAA Size: Fact or Fiction? | 2.0 | 2 | Citations (PDF) |
| 529 | Contrast-Induced Nephropathy and the Vascular Patient | 2.0 | 20 | Citations (PDF) |
| 530 | Trials by Independent Expert Bodies | 8.9 | 0 | Citations (PDF) |
| 531 | Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population | 2.2 | 91 | Citations (PDF) |
| 532 | Statin-fibrate combination for mixed dyslipidaemia: a limited option? | 2.2 | 7 | Citations (PDF) |
| 533 | Aortic Pulse Wave Velocity May Have Prognostic Value Not Just for Hypertension but Also for Abdominal Aortic Aneurysms | 7.0 | 2 | Citations (PDF) |
| 534 | Review Article: Effects of Plant Sterols and Stanols Beyond Low-Density Lipoprotein Cholesterol Lowering | 2.8 | 45 | Citations (PDF) |
| 535 | Lipid-lowering agents and new onset diabetes mellitus | 2.3 | 13 | Citations (PDF) |
| 536 | Ankle—Brachial Index: A Marker of Both Peripheral Arterial Disease and Systemic Atherosclerosis As Well As a Predictor of Vascular Events | 2.0 | 41 | Citations (PDF) |
| 537 | Statins may not prevent structural valve degeneration of aortic bioprosthetic valves, but should probably be prescribed to patients undergoing heart valve surgery nonetheless | 1.5 | 7 | Citations (PDF) |
| 538 | Endovascular Versus Open Repair of Abdominal Aortic Aneurysms: Interpreting the Landmark United Kingdom EVAR 1 Results | 1.7 | 2 | Citations (PDF) |
| 539 | Ezetimibe in diabetes: more than cholesterol lowering? | 2.2 | 17 | Citations (PDF) |
| 540 | The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases | 1.4 | 87 | Citations (PDF) |
| 541 | Seasonal variation in the occurrence of stroke in Northern Greece: a 10 year study in 8204 patients | 1.5 | 24 | Citations (PDF) |
| 542 | Severe, But Not Moderate, Carotid Atherosclerosis May Predict Concomitant Vascular Disease in Other Arterial Beds | 6.2 | 5 | Citations (PDF) |
| 543 | Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes: A Prospective Randomized Double-Blind Clinical Trial | 9.5 | 2 | Citations (PDF) |
| 544 | Undertreatment of hypercholesterolemia | 2.2 | 10 | Citations (PDF) |
| 545 | Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect? | 2.2 | 18 | Citations (PDF) |
| 546 | Statins and Heart Failure | 2.6 | 9 | Citations (PDF) |
| 547 | Mechanisms to explain the poor results of carotid artery stenting (CAS) in symptomatic patients to date and options to improve CAS outcomes | 1.6 | 50 | Citations (PDF) |
| 548 | To switch (statins) or not to switch? That is the question | 2.3 | 6 | Citations (PDF) |
| 549 | The effect of smoking on arterial stiffness | 3.4 | 157 | Citations (PDF) |
| 550 | Takotsubo cardiomyopathy — The current state of knowledge | 2.2 | 76 | Citations (PDF) |
| 551 | Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study | 2.0 | 217 | Citations (PDF) |
| 552 | Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis | 35.3 | 563 | Citations (PDF) |
| 553 | Metformin and cancer: licence to heal? | 4.1 | 33 | Citations (PDF) |
| 554 | Atorvastatin: safety and tolerability | 2.8 | 38 | Citations (PDF) |
| 555 | The role of Toll-like receptors in renal diseases | 13.6 | 147 | Citations (PDF) |
| 556 | Dapagliflozin: more than just another oral glucose-lowering agent? | 4.1 | 36 | Citations (PDF) |
| 557 | Could carbon monoxide and bilirubin be friends as well as foes of the body? | 1.3 | 20 | Citations (PDF) |
| 558 | Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications | 2.6 | 136 | Citations (PDF) |
| 559 | Regulation of inducible nitric oxide synthase activity/expression in rat hearts from ghrelin-treated rats | 3.6 | 25 | Citations (PDF) |
| 560 | Aliskiren, a Direct Renin Inhibitor, in Clinical Practice: A New Approach in the Treatment of Hypertension | 1.4 | 10 | Citations (PDF) |
| 561 | Management of Statin-Intolerant High-Risk Patients | 1.4 | 16 | Citations (PDF) |
| 562 | Endocrine Hypertension: Diagnosis and Management of a Complex Clinical Entity | 1.4 | 16 | Citations (PDF) |
| 563 | The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases | 1.4 | 3 | Citations (PDF) |
| 564 | Cholesteryl Ester Transfer Protein Gene Polymorphisms and Longevity Syndrome | 0.2 | 20 | Citations (PDF) |
| 565 | Increased Fluorodeoxyglucose Uptake Following Endovascular Abdominal Aortic Aneurysm Repair: A Predictor of Endoleak? | 0.2 | 3 | Citations (PDF) |
| 566 | Involvement of Signaling Molecules on Na+/H+ Exchanger-1 Activity in Human Monocytes | 0.2 | 8 | Citations (PDF) |
| 567 | Cholesteryl Ester Transfer Protein Gene and Effectiveness of Lipid Lowering of Atorvastatin | 0.2 | 7 | Citations (PDF) |
| 568 | Cardiovascular Risk Factors and Peripheral Arterial Disease 2010, , 165-172 | | 0 | Citations (PDF) |
| 569 | Kidney Function and Estimated Vascular Risk in Patients with Primary Dyslipidemia | 0.2 | 4 | Citations (PDF) |
| 570 | Adrenal incidentaloma: a diagnostic challenge | 2.0 | 62 | Citations (PDF) |
| 571 | JUPITER: major implications for vascular risk assessment | 2.2 | 8 | Citations (PDF) |
| 572 | Vernakalant hydrochloride for the treatment of atrial fibrillation | 4.1 | 15 | Citations (PDF) |
| 573 | Mortality after First Myocardial Infarction in Greek Patients: A 4-Year Follow-Up Study | 2.0 | 4 | Citations (PDF) |
| 574 | Aortic stiffness in diabetes mellitus – association with glutamine and heat shock protein 70 expression: a pilot study based on an experimental rodent model | 3.9 | 11 | Citations (PDF) |
| 575 | The Impact of Novel Treatment Modalities on the Therapeutic Approach of Cardiovascular Diseases | 2.0 | 1 | Citations (PDF) |
| 576 | Dyslipidemia as a Risk Factor for Ischemic Stroke | 2.7 | 75 | Citations (PDF) |
| 577 | Anti-Inflammatory Effects of Fibrates: An Overview | 2.5 | 20 | Citations (PDF) |
| 578 | Irradiation-Induced Carotid Artery Stenosis: A Preventable Complication of Neck Radiotherapy? | 2.0 | 4 | Citations (PDF) |
| 579 | Carotid Artery Stenting May Be Losing the Battle against Carotid Endarterectomy for the Management of Symptomatic Carotid Artery Stenosis, But the Jury Is Still Out | 1.2 | 10 | Citations (PDF) |
| 580 | Lipid Profile, Low-Density Lipoprotein Oxidation and Ceruloplasmin in the Progeny of Families with a Positive History of Cardiovascular Diseases and/or Hyperlipidemia | 2.0 | 8 | Citations (PDF) |
| 581 | Is High-sensitivity C-reactive Protein Associated with Subclinical Peripheral Atherosclerosis? | 2.0 | 5 | Citations (PDF) |
| 582 | Acute Limb Ischemia Caused by Femoral Arterial Line Induces Remote Liver Injury in a Rabbit Model of Liver Ischemia/Reperfusion Injury | 2.0 | 7 | Citations (PDF) |
| 583 | Percutaneous Coronary Interventions Affect Concentrations of Interleukin 6 and Its Soluble Receptors in Coronary Sinus Blood in Patients with Stable Angina | 2.0 | 5 | Citations (PDF) |
| 584 | Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced Type 1 diabetes | 2.6 | 72 | Citations (PDF) |
| 585 | Erectile dysfunction: a warning sign of silent vascular disease | 1.5 | 3 | Citations (PDF) |
| 586 | The mechanisms of atrial fibrillation in hyperthyroidism | 1.5 | 77 | Citations (PDF) |
| 587 | Arteriovenous Fistula Leading to Severe Tortuosity and Aneurysm Formation | 0.9 | 1 | Citations (PDF) |
| 588 | A Comparison of the Aldosterone‐blocking Agents Eplerenone and Spironolactone | 2.1 | 3 | Citations (PDF) |
| 589 | Deterioro de la función renal en la arteriopatía periférica: un parámetro que no debe ser infravalorado | 0.0 | 0 | Citations (PDF) |
| 590 | Endothelial Dysfunction in Patients with Noncomplicated and Complicated Hypertension | 3.0 | 25 | Citations (PDF) |
| 591 | Sex-associated effect of CETP and LPL polymorphisms on postprandial lipids in familial hypercholesterolaemia | 3.8 | 36 | Citations (PDF) |
| 592 | The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis | 4.4 | 480 | Citations (PDF) |
| 593 | Statins and venous thromboembolism: a novel effect of statins? | 2.2 | 12 | Citations (PDF) |
| 594 | Role and significance of statins in the treatment of hypertensive patients | 2.2 | 35 | Citations (PDF) |
| 595 | Bilirubin and peripheral arterial disease: 15 years later | 3.9 | 4 | Citations (PDF) |
| 596 | Drug-induced fibrotic valvular heart disease | 35.3 | 124 | Citations (PDF) |
| 597 | Anaesthetic techniques for carotid surgery | 35.3 | 4 | Citations (PDF) |
| 598 | Renal Function Impairment in Peripheral Arterial Disease: An Important Parameter that Should not Be Neglected | 1.2 | 42 | Citations (PDF) |
| 599 | L'insuffisance rénale dans la maladie artérielle périphérique : Un paramètre important qui ne devrait pas être négligé | 0.0 | 0 | Citations (PDF) |
| 600 | Lipoprotein a: where are we now? | 1.8 | 51 | Citations (PDF) |
| 601 | Primary and Secondary Hypertriglyceridaemia | 2.0 | 28 | Citations (PDF) |
| 602 | The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women | 2.3 | 18 | Citations (PDF) |
| 603 | Pleiotropic Effects of Statins - Clinical Evidence | 2.3 | 134 | Citations (PDF) |
| 604 | Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies | 2.0 | 26 | Citations (PDF) |
| 605 | Editorial: [Statins and Cardiovascular Events in Patients with End-Stage Renal Disease on Hemodialysis. The AURORA Results Suggest the Need for Earlier Intervention] | 1.4 | 8 | Citations (PDF) |
| 606 | Incidence of end-stage renal disease in the elderly: a steadily rising global socioeconomic epidemic | 1.5 | 10 | Citations (PDF) |
| 607 | Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis | 1.5 | 30 | Citations (PDF) |
| 608 | Circadian changes in the hemostatic system in healthy men and patients with cardiovascular diseases | 1.3 | 39 | Citations (PDF) |
| 609 | Implementation of Guidelines for the Management of Arterial Hypertension. The Impulsion Study | 0.2 | 16 | Citations (PDF) |
| 610 | The Link Between Human and Transgenic Animal Studies Involving Postprandial Hypertriglyceridemia and CETP Gene Polymorphisms | 0.2 | 5 | Citations (PDF) |
| 611 | Evaluation of Aortic Stiffness (Aortic Pulse–Wave Velocity) Before and After Elective Abdominal Aortic Aneurysm Repair Procedures: A Pilot Study# | 0.2 | 20 | Citations (PDF) |
| 612 | Purinergic receptor‐mediated effects of ATP in high‐grade bladder cancer | 3.5 | 52 | Citations (PDF) |
| 613 | Omega-3 fatty acids: How can they be used in secondary prevention? | 4.9 | 12 | Citations (PDF) |
| 614 | Multiple actions of high-density lipoprotein | 1.8 | 174 | Citations (PDF) |
| 615 | ¿Qué papel desempeña la diabetes mellitus en las tasas de reestenosis y permeabilidad tras la revascularización infrainginal? Revisión crítica | 0.0 | 0 | Citations (PDF) |
| 616 | Characterization of calcium‐independent purinergic receptor‐mediated apoptosis in hormone‐refractory prostate cancer | 3.5 | 43 | Citations (PDF) |
| 617 | A functional study of purinergic signalling in the normal and pathological rabbit corpus cavernosum | 3.5 | 14 | Citations (PDF) |
| 618 | Effect of extracellular ATP on the growth of hormone-refractory prostate cancer in vivo | 3.5 | 48 | Citations (PDF) |
| 619 | Effectiveness of Ezetimibe Alone or in Combination With Twice a Week Atorvastatin (10 mg) for Statin Intolerant High-Risk Patients | 1.9 | 64 | Citations (PDF) |
| 620 | Effects of Simvastatin Alone Versus Fenofibrate Alone Versus Simvastatin Plus Fenofibrate on Lipoprotein Subparticle Profiles in Patients With Diabetes Mellitus and Mixed Dyslipidemia | 1.9 | 3 | Citations (PDF) |
| 621 | Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality | 2.8 | 57 | Citations (PDF) |
| 622 | Does Diabetes Mellitus Play a Role in Restenosis and Patency Rates Following Lower Extremity Peripheral Arterial Revascularization? A Critical Overview | 1.2 | 58 | Citations (PDF) |
| 623 | Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention? | 3.9 | 11 | Citations (PDF) |
| 624 | Antisense technology for the prevention or the treatment of cardiovascular disease: The next blockbuster? | 4.1 | 8 | Citations (PDF) |
| 625 | Elevated heart rate and atherosclerosis: An overview of the pathogenetic mechanisms | 2.2 | 202 | Citations (PDF) |
| 626 | Vascular risk factors in South Asians | 2.2 | 44 | Citations (PDF) |
| 627 | Obesity and postoperative atrial fibrillation. Is there no connection? | 2.9 | 3 | Citations (PDF) |
| 628 | The role of fibrinogen and fibrinolysis in peripheral arterial disease | 2.4 | 53 | Citations (PDF) |
| 629 | Do we need to consider inflammatory markers when we treat atherosclerotic disease? | 1.2 | 76 | Citations (PDF) |
| 630 | Le diabète joue-t-il un rôle dans les resténoses et les taux de perméabilité après revascularisation artérielle des membres inferieurs ? une étude générale critique | 0.0 | 0 | Citations (PDF) |
| 631 | Lipid abnormalities and cardiovascular risk in the elderly | 2.2 | 9 | Citations (PDF) |
| 632 | C-reactive protein (CRP): more than just an innocent bystander? | 2.2 | 41 | Citations (PDF) |
| 633 | Achieving Vascular Risk Factor Targets: A Survey of a London General Practice | 2.0 | 9 | Citations (PDF) |
| 634 | Smoking, Abdominal Aortic Aneurysms, and Ischemic Heart Disease: Is There a Link? | 2.0 | 10 | Citations (PDF) |
| 635 | Statins and Heart Failure | 2.0 | 9 | Citations (PDF) |
| 636 | The significance of preoperative atrial fibrillation in patients undergoing cardiac surgery: preoperative atrial fibrillation--still underestimated opponent | 1.9 | 42 | Citations (PDF) |
| 637 | Clinical significance of carotid bruits: an innocent finding or a useful warning sign? | 1.5 | 14 | Citations (PDF) |
| 638 | Association between plasma levels and immunolocalization of cytokines in heart valve lesions: a possible target for treatment? | 3.9 | 18 | Citations (PDF) |
| 639 | Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective? | 2.3 | 6 | Citations (PDF) |
| 640 | Does Gender Influence the Patency of Infrainguinal Bypass Grafts? | 2.0 | 13 | Citations (PDF) |
| 641 | Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism | 2.3 | 106 | Citations (PDF) |
| 642 | Apolipoprotein E Knockout Models | 2.3 | 66 | Citations (PDF) |
| 643 | Experimental Models of Abdominal Aortic Aneurysms: An Overview | 2.3 | 14 | Citations (PDF) |
| 644 | CORONA, Statins, and Heart Failure: Who Lost the Crown? | 2.0 | 5 | Citations (PDF) |
| 645 | <i>Cholesterol Crystal Embolization</i>:<b>A Possible Complication of Peripheral Endovascular Interventions</b> | 1.7 | 17 | Citations (PDF) |
| 646 | Are Statins an Option in the Management of Abdominal Aortic Aneurysms? | 0.7 | 22 | Citations (PDF) |
| 647 | Soluble but Not Platelet P-selectin Correlates With Spontaneous Platelet Aggregation: A Pilot Study | 1.8 | 10 | Citations (PDF) |
| 648 | Do Different Vascular Risk Factors Affect All Arteries Equally? | 2.0 | 19 | Citations (PDF) |
| 649 | Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas | 4.5 | 24 | Citations (PDF) |
| 650 | The Effect of Tirofiban on Fibrinogen/Agonist-Induced Platelet Shape Change and Aggregation | 1.8 | 13 | Citations (PDF) |
| 651 | Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study | 2.2 | 19 | Citations (PDF) |
| 652 | Statin discontinuation: an underestimated risk? | 2.2 | 42 | Citations (PDF) |
| 653 | Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended? | 4.1 | 8 | Citations (PDF) |
| 654 | High Density Lipoprotein Cholesterol and Statin Trials | 2.5 | 14 | Citations (PDF) |
| 655 | Sodium-Lithium Countertransport Activity in Healthy, Dyslipidemic, and Hypertensive Individuals | 2.0 | 1 | Citations (PDF) |
| 656 | Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study | 2.2 | 24 | Citations (PDF) |
| 657 | Editorial: [Pleiotropic Effects of Statins: Implications for a Wide Range of Diseases] | 1.4 | 22 | Citations (PDF) |
| 658 | Preventing macrovascular complications of diabetes: where do we stand with glycemic control? | 4.1 | 5 | Citations (PDF) |
| 659 | Association Between Ankle - Brachial Index and Risk Factor Profile in Patients Newly Diagnosed With Intermittent Claudication | 1.8 | 43 | Citations (PDF) |
| 660 | The Role of Trimetazidine After Acute Myocardial Infarction | 1.4 | 7 | Citations (PDF) |
| 661 | Editorial [ Angiogenesis: A Promising Treatment Option for Peripheral Arterial Disease ] | 1.4 | 7 | Citations (PDF) |
| 662 | Multiple actions of high-density lipoprotein | 0.6 | 0 | Citations (PDF) |
| 663 | Additional Effects of Statins in Surgical Patients | 4.9 | 2 | Citations (PDF) |
| 664 | Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus | 1.8 | 9 | Citations (PDF) |
| 665 | Acute and long-term antiplatelet therapy | 1.9 | 2 | Citations (PDF) |
| 666 | Oxidative Stress As A Common Mediator for Apoptosis Induced-Cardiac Damage in Diabetic Rats | 0.2 | 32 | Citations (PDF) |
| 667 | The Impact of Lower Extremity Venous Ulcers due to Chronic Venous Insufficiency on Quality of Life~!2008-11-17~!2008-11-19~!2008-11-28~! | 0.2 | 17 | Citations (PDF) |
| 668 | Statin Treatment, Carotid Atherosclerotic Plaque Macrophage Infiltration and Circulating Inflammatory Markers | 0.2 | 10 | Citations (PDF) |
| 669 | Low HDL Cholesterol, Smoking and IL-13 R130Q Polymorphism are Associated with Myocardial Infarction in Greek Cypriot Males. A Pilot Study | 0.2 | 3 | Citations (PDF) |
| 670 | Statins and Cholesterol: How Low Can You Go? 2008, , 179-186 | | 0 | Citations (PDF) |
| 671 | Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia? | 2.3 | 10 | Citations (PDF) |
| 672 | Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects | 2.3 | 20 | Citations (PDF) |
| 673 | Atenolol: Differences in Mode of Action Compared with other Antihypertensives.An Opportunity to Identify Features that Influence Outcome? | 2.3 | 11 | Citations (PDF) |
| 674 | Optical Techniques in the Assessment of Peripheral Arterial Disease | 1.4 | 56 | Citations (PDF) |
| 675 | Pharmacological treatment of non-alcoholic steatohepatitis: The current evidence | 1.8 | 15 | Citations (PDF) |
| 676 | Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications | 2.3 | 81 | Citations (PDF) |
| 677 | Statins and renal function. Is the compound and dose making a difference? | 0.8 | 17 | Citations (PDF) |
| 678 | The role of renin–angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal? | 3.9 | 22 | Citations (PDF) |
| 679 | Association of Drinking Pattern and Alcohol Beverage Type With the Prevalence of Metabolic Syndrome, Diabetes, Coronary Heart Disease, Stroke, and Peripheral Arterial Disease in a Mediterranean Cohort | 2.0 | 127 | Citations (PDF) |
| 680 | Endothelial function, arterial stiffness and lipid lowering drugs | 3.9 | 35 | Citations (PDF) |
| 681 | Internal Carotid Artery Occlusion: Association With Atherosclerotic Disease in Other Arterial Beds and Vascular Risk Factors | 2.0 | 43 | Citations (PDF) |
| 682 | Platelet Activation in Bypass Surgery for Critical Limb Ischemia | 0.7 | 3 | Citations (PDF) |
| 683 | Management of a Patient With a Null Low-Density Lipoprotein Receptor Mutation | 2.0 | 11 | Citations (PDF) |
| 684 | The Relationship Between Circulating Fibrinogen and Lipoprotein (a) Levels in Patients With Primary Dyslipidemia | 1.8 | 8 | Citations (PDF) |
| 685 | Statins and Regression of Coronary Atherosclerosis | 13.7 | 7 | Citations (PDF) |
| 686 | Association between the TaqIB polymorphism in the cholesteryl ester transfer protein gene locus and postprandial plasma lipoprotein levels in heterozygotes for familial hypercholesterolemia | 2.7 | 17 | Citations (PDF) |
| 687 | Editorial [PCI and Stable Coronary Heart Disease - COURAGE to Change Our Minds?] | 1.4 | 1 | Citations (PDF) |
| 688 | Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles | 3.2 | 84 | Citations (PDF) |
| 689 | Prospective Assessment of Lower-Extremity Peripheral Arterial Disease in Diabetic Patients Using a Novel Automated Optical Device | 2.0 | 33 | Citations (PDF) |
| 690 | Statins Exert Multiple Beneficial Effects on Patients Undergoing Percutaneous Revascularization Procedures | 2.0 | 43 | Citations (PDF) |
| 691 | The Effect of Statins on Postprandial Lipemia | 2.0 | 30 | Citations (PDF) |
| 692 | Identifying and Attaining LDL-C Goals: Mission Accomplished? Next Target: New Therapeutic Options to Raise HDL-C Levels | 2.0 | 25 | Citations (PDF) |
| 693 | The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome | 2.1 | 35 | Citations (PDF) |
| 694 | Thromboangiitis Obliterans (Buerger’s Disease): Searching for a Therapeutic Strategy | 2.0 | 26 | Citations (PDF) |
| 695 | Metallothionein expression in the high-risk carotid atherosclerotic plaque | 2.2 | 13 | Citations (PDF) |
| 696 | Angiotensin II reactivation and aldosterone escape phenomena in renin–angiotensin–aldosterone system blockade: is oral renin inhibition the solution? | 2.3 | 64 | Citations (PDF) |
| 697 | The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes | 2.3 | 10 | Citations (PDF) |
| 698 | Shape of the Nations survey and attitudes to cardiometabolic risk | 2.2 | 10 | Citations (PDF) |
| 699 | Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin | 2.2 | 76 | Citations (PDF) |
| 700 | Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia | 2.2 | 98 | Citations (PDF) |
| 701 | Statins: An essential component in the management of carotid artery disease | 1.6 | 75 | Citations (PDF) |
| 702 | Serum Uric Acid as an Independent Predictor of Early Death After Acute Stroke | 1.8 | 104 | Citations (PDF) |
| 703 | Gene therapy and erectile dysfunction: the current status | 2.1 | 12 | Citations (PDF) |
| 704 | Pheochromocytoma: an update on genetics and management | 4.5 | 96 | Citations (PDF) |
| 705 | Atorvastatin Decreases Triacylglycerol‐Associated Risk of Vascular Events in Coronary Heart Disease Patients | 1.5 | 34 | Citations (PDF) |
| 706 | Analysis of antihypertensive effects of statins | 5.1 | 21 | Citations (PDF) |
| 707 | Should a statin be prescribed to every patient with heart failure? | 3.6 | 17 | Citations (PDF) |
| 708 | Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients§ | 0.2 | 25 | Citations (PDF) |
| 709 | Peripheral Arterial Disease and Emerging Biochemical Vascular Risk Factors 2007, , 111-116 | | 0 | Citations (PDF) |
| 710 | Lipids and Peripheral Arterial Disease 2007, , 35-40 | | 0 | Citations (PDF) |
| 711 | The Role of Serotonin (5-Hydroxytryptamine
1A
and
1B
) Receptors in Prostate Cancer Cell Proliferation | 4.4 | 72 | Citations (PDF) |
| 712 | Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study | 2.2 | 222 | Citations (PDF) |
| 713 | Ezetimibe/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia | 2.2 | 6 | Citations (PDF) |
| 714 | Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe | 2.2 | 50 | Citations (PDF) |
| 715 | The Effect of Apolipoprotein E Polymorphism on the Response to Lipid-Lowering Treatment With Atorvastatin or Fenofibrate | 2.8 | 34 | Citations (PDF) |
| 716 | Doxazosin and Serotonin (5‐HT) Receptor (1A, 2A, and 4) Antagonists Inhibit 5‐HT‐Mediated Human Cavernosal Contraction | 2.5 | 14 | Citations (PDF) |
| 717 | Treating to target patients with primary hyperlipidaemia:comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study) | 2.2 | 56 | Citations (PDF) |
| 718 | Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? | 5.0 | 215 | Citations (PDF) |
| 719 | Metabolic syndrome and gender differences in postprandial lipaemia | 2.8 | 30 | Citations (PDF) |
| 720 | Exorcising Ghosts and Unwelcome Guests | 10.5 | 2 | Citations (PDF) |
| 721 | Smooth Muscle and Purinergic Contraction of the Human, Rabbit, Rat, and Mouse Testicular Capsule1 | 2.7 | 32 | Citations (PDF) |
| 722 | Leptin: A Promising Therapeutic Target with Pleiotropic Action Besides Body Weight Regulation | 2.0 | 24 | Citations (PDF) |
| 723 | The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation | 3.5 | 65 | Citations (PDF) |
| 724 | Statins and Peripheral Arterial Disease: Potential Mechanisms and Clinical Benefits | 1.2 | 45 | Citations (PDF) |
| 725 | The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol | 1.5 | 91 | Citations (PDF) |
| 726 | The Effect of Cholesterol-Lowering Treatment on Renal Function | 5.6 | 14 | Citations (PDF) |
| 727 | Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study | 0.8 | 138 | Citations (PDF) |
| 728 | Combined Treatment With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: A Review of the Current Evidence | 2.8 | 30 | Citations (PDF) |
| 729 | Definitions of Metabolic Syndrome: Where are We Now? | 1.4 | 36 | Citations (PDF) |
| 730 | The Management of Phosphodiesterase-5 (PDE5) Inhibitor Failure | 1.4 | 30 | Citations (PDF) |
| 731 | The Role of Thiols in Liver Ischemia-Reperfusion Injury | 2.3 | 38 | Citations (PDF) |
| 732 | Lipid Lowering Therapy in the Elderly: Is there a Benefit? | 2.3 | 10 | Citations (PDF) |
| 733 | Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: Where we are now? | 2.5 | 44 | Citations (PDF) |
| 734 | Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): Response to Knopp | 9.5 | 7 | Citations (PDF) |
| 735 | Dyslipidaemia, Hypercoagulability and the Metabolic Syndrome | 1.4 | 39 | Citations (PDF) |
| 736 | Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview | 3.9 | 29 | Citations (PDF) |
| 737 | Alcohol Use, Vascular Disease, and Lipid-Lowering Drugs | 3.5 | 24 | Citations (PDF) |
| 738 | Oral and ocular/orbital manifestations of temporal arteritis: a disease with deceptive clinical symptoms and devastating consequences | 2.3 | 40 | Citations (PDF) |
| 739 | Cardiovascular Risk Factors and Peripheral Arterial Disease 2006, , 133-140 | | 0 | Citations (PDF) |
| 740 | The role of serotonin in tumour growth (Review) | 2.4 | 25 | Citations (PDF) |
| 741 | In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit | 3.5 | 0 | Citations (PDF) |
| 742 | Endothelin-1 and Human Platelets | 1.4 | 28 | Citations (PDF) |
| 743 | Mean platelet volume in patients with type 2 diabetes mellitus | 2.5 | 6 | Citations (PDF) |
| 744 | Risk Modification in Patients with Peripheral Arterial Disease: A Retrospective Survey | 2.0 | 37 | Citations (PDF) |
| 745 | Editorial [Hot Topic: Biochemical and Clinical Relevance of Hyperuricaemia (Executive Editor: Dimitri P. Mikhailidis Associate Editor: Stella S. Daskalopoulou)] | 2.3 | 0 | Citations (PDF) |
| 746 | Clinical Relevance of Postprandial Lipaemia | 2.5 | 111 | Citations (PDF) |
| 747 | Components of the Metabolic Syndrome and Risk for First-Ever Acute Ischemic Nonembolic Stroke in Elderly Subjects | 6.2 | 102 | Citations (PDF) |
| 748 | Effect of Antihypertensive Treatment on PlasmaFibrinogen and Serum HDL Levelsin Patients with Essential Hypertension | 1.8 | 17 | Citations (PDF) |
| 749 | Fenofibrate: Metabolic and Pleiotropic Effects | 1.4 | 54 | Citations (PDF) |
| 750 | Peripheral Arterial Disease: A Missed Opportunity to Administer Statins so as to Reduce Cardiac Morbidity and Mortality | 2.5 | 49 | Citations (PDF) |
| 751 | Association of Apolipoprotein E Genotype with Early Onset of Coronary Heart Disease in Greek Men | 2.0 | 22 | Citations (PDF) |
| 752 | New-onset diabetes after transplantation | 35.3 | 3 | Citations (PDF) |
| 753 | Increased platelet purinergic sensitivity in peripheral arterial disease – A pilot study | 2.5 | 9 | Citations (PDF) |
| 754 | The involvement of professional medical writers in medical publications | 2.2 | 22 | Citations (PDF) |
| 755 | A review of the lipid-related effects of fluvastatin | 2.2 | 35 | Citations (PDF) |
| 756 | Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease.A subgroup analysis of the GREACE study | 2.5 | 26 | Citations (PDF) |
| 757 | Targeting vascular risk in patients with metabolic syndrome but without diabetes | 5.0 | 60 | Citations (PDF) |
| 758 | The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions | 2.2 | 158 | Citations (PDF) |
| 759 | Effect of atorvastatin on highdensity lipoprotein cholesteroland its relationship withcoronary events: a subgroupanalysis of the GREekAtorvastatin and Coronary-heart-disease Evaluation (GREACE) Study | 2.2 | 65 | Citations (PDF) |
| 760 | Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study | 2.2 | 80 | Citations (PDF) |
| 761 | The Effect of Short-Term Treatment with Simvastatin on Renal Function in Patients with Peripheral Arterial Disease | 2.0 | 73 | Citations (PDF) |
| 762 | Combination Antiplatelet Therapy in Patients with Peripheral Vascular Bypass Grafts | 1.8 | 13 | Citations (PDF) |
| 763 | Effect of Fenofibrate on Serum Inflammatory Markers in Patients With High Triglyceride Values | 2.8 | 57 | Citations (PDF) |
| 764 | Erectile dysfunction: a need for greater awareness | 0.2 | 3 | Citations (PDF) |
| 765 | The impact of serum uric acid on cardiovascular outcomes in the LIFE study | 5.6 | 28 | Citations (PDF) |
| 766 | Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the greek atorvastatin and coronary-heart-disease evaluation (GREACE) study | 5.6 | 209 | Citations (PDF) |
| 767 | Clopidogrel and vascular disease prevention | 2.2 | 4 | Citations (PDF) |
| 768 | The Influence of Natural Menopause on Postprandial Lipemia in Heterozygotes for Familial Hypercholesterolemia | 2.2 | 17 | Citations (PDF) |
| 769 | Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study | 2.2 | 14 | Citations (PDF) |
| 770 | The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease | 2.5 | 63 | Citations (PDF) |
| 771 | Effect of tibolone on markers of cardiovascular disease risk in postmenopausal women undergoing hemodialysis: a pilot study | 1.2 | 14 | Citations (PDF) |
| 772 | Metabolic Syndrome: Clinical Features Leading to Therapeutic Strategies | 0.0 | 13 | Citations (PDF) |
| 773 | Direct measurement of hepatic tissue hypoxia by using a novel tc<i>p</i>O<sub>2</sub>/<i>p</i>CO<sub>2</sub> monitoring system in comparison with near‐infrared spectroscopy | 4.2 | 16 | Citations (PDF) |
| 774 | More on PROSPER | 35.3 | 9 | Citations (PDF) |
| 775 | Influence of platelet count and activity on thromboelastography parameters | 2.5 | 76 | Citations (PDF) |
| 776 | Early vascular benefits of statin therapy | 2.2 | 144 | Citations (PDF) |
| 777 | Influence of Smoking on Predictors of Vascular Disease | 2.0 | 115 | Citations (PDF) |
| 778 | Value of Thromboelastography in the Assessment of Platelet Function | 1.8 | 51 | Citations (PDF) |
| 779 | Apolipoprotein E Polymorphism and Atherosclerosis | 2.0 | 42 | Citations (PDF) |
| 780 | The Epsilon 2 and 4 Alleles of Apolipoprotein E and Ischemic Vascular Events in the Greek Population — Implications for the Interpretation of Similar Studies | 2.0 | 26 | Citations (PDF) |
| 781 | The Effect of a Loading Dose (300 mg) of Clopidogrel on Platelet Function in Patients with Peripheral Arterial Disease | 1.8 | 26 | Citations (PDF) |
| 782 | Ghrelin Can Bind to a Species of High Density Lipoprotein Associated with Paraoxonase | 2.3 | 115 | Citations (PDF) |
| 783 | Both the ADP receptors P2Y 1 and P2Y 12 , play a role in controlling shape change in human platelets | 2.5 | 47 | Citations (PDF) |
| 784 | Statins and renal function in patients with diabetes mellitus | 2.2 | 62 | Citations (PDF) |
| 785 | Platelets as Predictors of Vascular Risk: Is There a Practical Index of Platelet Activity? | 1.8 | 238 | Citations (PDF) |
| 786 | γ-Glutamyltransferase and Vascular Disease | 1.1 | 6 | Citations (PDF) |
| 787 | Mean platelet volume as an indicator of platelet activation: methodological issues | 2.5 | 32 | Citations (PDF) |
| 788 | The Effect of Graded Systemic Hypoxaemia on Hepatic Tissue Oxygenation | 0.0 | 2 | Citations (PDF) |
| 789 | The Effects of Lipid-Regulating Therapy on Haemostatic Parameters | 2.3 | 33 | Citations (PDF) |
| 790 | Statins and Renal Function | 2.0 | 88 | Citations (PDF) |
| 791 | Attaining United Kingdom-European Atherosclerosis Society Low-density Lipoprotein Cholesterol Guideline Target Values in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study | 2.2 | 14 | Citations (PDF) |
| 792 | Effect of Ciprofibrate on C-Reactive Protein and Fibrinogen Levels | 2.0 | 48 | Citations (PDF) |
| 793 | A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors | 5.6 | 142 | Citations (PDF) |
| 794 | Effect of Ciprofibrate on Lipoproteins, Fibrinogen, Renal Function, and Hepatic Enzymes | 2.8 | 35 | Citations (PDF) |
| 795 | Beyond LDL-C – The Importance of Raising HDL-C | 2.2 | 42 | Citations (PDF) |
| 796 | Reduction of endothelin-1 binding and inhibition of endothelin-1-mediated detrusor contraction by naftidrofuryl | 6.3 | 3 | Citations (PDF) |
| 797 | A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women | 1.2 | 67 | Citations (PDF) |
| 798 | The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study | 2.2 | 37 | Citations (PDF) |
| 799 | The Choice of Antihypertensive Drugs in Patients with Erectile Dysfunction | 2.2 | 24 | Citations (PDF) |
| 800 | Dose–response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies | 2.2 | 41 | Citations (PDF) |
| 801 | The Effect of Clopidogrel (Plavix) on Platelet Function in Patients with Peripheral Vascular Disease ‐ Comparison with Aspirin | 0.9 | 2 | Citations (PDF) |
| 802 | Decreased urinary bladder apoptosis in a rabbit model of diabetes mellitus | 0.4 | 8 | Citations (PDF) |
| 803 | Measurement of atherosclerosis progression | 35.3 | 2 | Citations (PDF) |
| 804 | Smoking Diminishes the Beneficial Effect of Statins: Observations from the Landmark Trials | 2.0 | 49 | Citations (PDF) |
| 805 | Ciprofibrate Versus Gemfibrozil in the Treatment of Mixed Hyperlipidemias: An Open-Label, Multicenter Study | 5.0 | 2 | Citations (PDF) |
| 806 | The Treatment of Coronary Heart Disease: An Update Part 5: Selected Comments and Questions Compiled by | 2.2 | 0 | Citations (PDF) |
| 807 | The effect of nitric oxide and peroxynitrite on rabbit cavernosal smooth muscle relaxation | 2.4 | 38 | Citations (PDF) |
| 808 | The effect of sildenafil on corpus cavernosal smooth muscle relaxation and cyclic GMP formation in the diabetic rabbit | 4.4 | 57 | Citations (PDF) |
| 809 | Treating dyslipidaemia in non-insulin-dependent diabetes mellitus — a special reference to statins | 2.6 | 25 | Citations (PDF) |
| 810 | Effect of Atorvastatin on Serum Creatinine Levels | 2.2 | 21 | Citations (PDF) |
| 811 | Endothelin-1 and Urinary Bladder Hyperplasia Following Partial Bladder Outlet Obstruction | 2.1 | 4 | Citations (PDF) |
| 812 | Relaxation of rabbit lower urinary tract smooth muscle by nitric oxide and carbon monoxide: modulation by hydrogen peroxide | 4.4 | 18 | Citations (PDF) |
| 813 | Doxazosin modifies serotonin-mediated rabbit urinary bladder contraction | 0.4 | 13 | Citations (PDF) |
| 814 | Altered Cavernosal Endothelin-B-Receptor Binding Sites in the Rabbit Model of Partial Bladder Outlet Obstruction | 2.1 | 0 | Citations (PDF) |
| 815 | The Molecular Basis of Penile Erection | 2.2 | 6 | Citations (PDF) |
| 816 | The Use of Citrated Whole Blood in Thromboelastography | 1.8 | 86 | Citations (PDF) |
| 817 | Sildenafil: a Urologist's View | 2.2 | 5 | Citations (PDF) |
| 818 | HDL-cholesterol and the Treatment of Coronary Heart Disease: Contrasting Effects of Atorvastatin and Simvastatin | 2.2 | 49 | Citations (PDF) |
| 819 | The Treatment of Hypertension in Patients with Erectile Dysfunction | 2.2 | 23 | Citations (PDF) |
| 820 | Possible Role of Endothelin-1 in the Rabbit Urinary Bladder Hyperplasia Secondary to Partial Bladder Outlet Obstruction | 1.2 | 12 | Citations (PDF) |
| 821 | Time-dependent up-regulation of neuronal 5-hydroxytryptamine binding sites in the detrusor of a rabbit model of partial bladder outlet obstruction | 2.4 | 14 | Citations (PDF) |
| 822 | Down-regulation of endothelin-B receptor sites in cavernosal tissue of a rabbit model of partial bladder outlet obstruction: potential clinical relevance | 2.4 | 23 | Citations (PDF) |
| 823 | Differential Alterations of Spontaneous and Stimulated 45Ca2+ Uptake by Platelets from Patients with Type I and Type II Diabetes Mellitus | 2.6 | 4 | Citations (PDF) |
| 824 | Statin + fibrate combination therapy | 2.2 | 53 | Citations (PDF) |
| 825 | Endothelin and erectile dysfunction: a target for pharmacological intervention? | 4.1 | 12 | Citations (PDF) |
| 826 | Cigarette smoking and erectile dysfunction | 0.2 | 44 | Citations (PDF) |
| 827 | Unstable angina | 2.9 | 0 | Citations (PDF) |
| 828 | Triacylglycerol lowering properties of the adenosine analog GR 79236 during 5 days of dosing large, old rats: A pilot study | 2.9 | 1 | Citations (PDF) |
| 829 | Naftidrofuryl inhibits the release of 5-hydroxytryptamine and platelet-derived growth factor from human platelets | 1.2 | 23 | Citations (PDF) |
| 830 | Altered prostacyclin synthesis by aortae from hepatic portal vein-constricted rats: evidence for effects on protein kinase C and calcium | 2.9 | 17 | Citations (PDF) |
| 831 | Improvement of Ketoacidosis in the Diabetic Rat after the Administration of the Oral Antilipolytic Agent Gr 79236 | 6.3 | 14 | Citations (PDF) |
| 832 | Effect of milrinone on thromboxane A2 synthesis, cAMP phosphodiesterase and 45Ca2+ uptake by human platelets | 2.3 | 18 | Citations (PDF) |
| 833 | Effect of milrinone on human platelet shape change, aggregation and thromboxane A2 synthesis: An in vitro study | 2.4 | 31 | Citations (PDF) |
| 834 | A thesis for all seasons | 40.1 | 12 | Citations (PDF) |
| 835 | Differential inhibitory potencies of non-steroidal antiinflammatory drugs on smooth muscle prostanoid synthesis | 4.4 | 14 | Citations (PDF) |
| 836 | Muscarinic stimulation of prostanoid synthesis by the isolated rat trachea: calcium dependency and effect of cortisol and cigarette smoke | 4.4 | 5 | Citations (PDF) |
| 837 | Iron chelators inhibit human platelet aggregation, thromboxane A<sub>2</sub> synthesis and lipoxygenase activity | 2.8 | 48 | Citations (PDF) |
| 838 | Ethanol Ingestion Inhibits Human Whole Blood Platelet Impedance Aggregation | 0.6 | 37 | Citations (PDF) |
| 839 | Cyclosporine A enhances platelet aggregation | 5.6 | 113 | Citations (PDF) |
| 840 | Muscarinic stimulation of prostacyclin synthesis by the rat penis | 4.4 | 24 | Citations (PDF) |
| 841 | Thromboxane A2 analogue (U-46619) stimulates vascular PGI2 synthesis | 4.4 | 48 | Citations (PDF) |
| 842 | Adrenergic modulation of vascular prostacyclin (PGI2) secretion | 4.4 | 62 | Citations (PDF) |
| 843 | Effect of nonesterified fatty acids on the stability of prostacyclin activity | 5.0 | 68 | Citations (PDF) |
| 844 | Cilostazol for intermittent claudication | 2.4 | 110 | Citations (PDF) |
| 845 | Obstructive sleep apnea and cardiovascular disease: Is mean platelet volume one of the links? | 1.2 | 1 | Citations (PDF) |
| 846 | Epicardial fat: a novel marker of subclinical atherosclerosis in clinical practice? | 1.2 | 8 | Citations (PDF) |
| 847 | Alice through the Looking-glass: Can We Improve Peer Review? | 1.8 | 6 | Citations (PDF) |
| 848 | A Call to Encourage Participation in the Reviewing Process: The REFEREE Acrostic | 1.8 | 2 | Citations (PDF) |
